Smiles	Standard Type	Standard Relation	Standard Value	Standard Units	Assay Description
C[C@@H](NC(=O)N1C(=O)CC1Sc1ccccc1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CC[C@@H](NC(=O)N1C(=O)CC1SCc1ccccn1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CCCC(CCC)C(=O)N[C@H](C=O)Cc1c[nH]c2ccccc12	IC50	'>'	1000.0	nM	Inhibition of human cathepsin B
Cc1cccc(O[C@H]2CCN3C[C@H]2OC3=O)c1C	IC50	'='	1.0	nM	Inhibition of human recombinant cathepsin B
NC(=S)NN=C1c2ccccc2-c2ccccc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3ccccc23)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C1CCCCC1)C(C)C)C(=O)O	IC50	'>'	30000.0	nM	Inhibition of human cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	4807.0	nM	Potency against Cathepsin B in HepG2 cells by whole cell enzyme occupancy assay
O=C1O[C@@H]2CN1CC[C@@H]2OCc1ccccc1	IC50	'='	2.0	nM	Inhibition of human recombinant cathepsin B
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B pre-incubated for 24 hrs in assay buffer with DTT
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	45.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
COC(=O)[C@@H]1CCCN1C(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](OC(=O)[C@@H](OC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)[C@@H](C)O	IC50	'='	10000.0	nM	Inhibition of cathepsin B after 10 to 15 mins by fluorescence assay
CC(C)C[C@H](Nc1cccc(-c2ccc(N3CCNCC3)cc2)c1)C(=O)NCC#N	IC50	'='	93.0	nM	Inhibitory concentration against human cathepsin B
N#C[C@]1(NC(=O)C(N)Cc2cncs2)C[C@H]1c1ccccc1.O=C(O)C(F)(F)F	IC50				Inhibition of human recombinant cathepsin B after 10 mins
N#C[C@]1(NC(=O)[C@H](N)Cc2cccs2)C[C@H]1c1ccccc1.O=C(O)C(F)(F)F	IC50	'>'	50000.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
CC[C@H](C)[C@@H](C(=O)O[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)/C=C/C(=O)N1C(=O)C=C(OC)[C@@H]1C)N(C)C	IC50	'='	4200.0	nM	Inhibition of human Cathepsin B using Z-Phe-Arg-aminomethylcoumarin as substrate
N#CC1(NC(=O)[C@H](CS(=O)(=O)Cc2ccccc2-c2ccccc2)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	4041.0	nM	Inhibition of human cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)Cc2cccc(F)c2F)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	1319.0	nM	Inhibition of human cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)CC2CC2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	287.0	nM	Inhibition of human cathepsin B
C[S+]([O-])C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	8029.0	nM	Inhibition of human cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CC[S+]([O-])[C@@H]12)OCc1ccccc1	IC50	'='	16400.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
CC(C)C[C@H](N[C@@H](c1ccc(-c2ncccn2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	5903.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCN=C(N)N	IC50	'='	0.0049	ug.mL-1	Inhibitory activity against Cathepsin B was determined
Cc1ccc(S(=O)(=O)N2CCC[C@@H]2C(=O)N[C@H](C=O)Cc2ccccc2)cc1	IC50	'='	3600.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CC(O)C2)CC1	IC50	'='	63300.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)Nc2ccc(F)cc2)CC1	IC50	'>'	25000.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCC(O)CC2)CC1	IC50	'='	5700.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
COCc1nnc(-c2cccc(C[C@H](NC(=O)c3cc(C(C)(C)C)nn3C)C(=O)NCC#N)c2)o1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(-c2nnc(CO)o2)c1)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	29000.0	nM	Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CS(C)(=O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	140000.0	nM	Inhibition of cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)c1ccccc1	IC50				Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	20.0	nM	Inhibition of cathepsin D
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1ccc(C)cc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	396.0	nM	Inhibition of cathepsin D
CCCCS(=O)(=O)C[C@@H](NC(=O)c1ncc[nH]1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	606.0	nM	Inhibition of cathepsin D
CCCCS(=O)(=O)C[C@@H](NC(=O)C1CC1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	446.0	nM	Inhibition of cathepsin D
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccc(F)cc2)o1)C(C)(C)C)C(=O)C(=O)NCc1cccnc1	IC50	'='	18000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(Br)cc2C(F)(F)F)CN1c1cc(C)nn1C1CCC1)C(=O)C(=O)NC1CC1	IC50	'='	1298.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)C[C@@H](C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(C)CC3)cc2)c1	IC50	'='	2599.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(C(C)(C)C)CC3)cc2)c1	IC50	'='	379.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCC[C@@H](C=O)NC(=O)OC1(Cc2ccccc2)CCCC1	IC50	'='	810.0	nM	Inhibitory concentration against recombinant human cathepsin B was determined in a fluorescence assay using 10 uM Cbz-Phe-Arg-AMC as substrate
CCCC[C@H](NC(=O)O[C@H]1CCCc2ccccc21)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	2000.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
CCCC[C@H](NC(=O)OC1C2(C)CCC(C2)C1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	12000.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
CC(=O)c1c(Nc2ccc(Br)cc2)[nH]c2c(Br)ccc(Br)c2c1=O	IC50	'='	1640.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
O=C(N[C@@H](CC1CCCCC1)C(=O)N[C@@H]1C(=O)N2CCS(=O)(=O)[C@@H]12)OCc1ccccc1	IC50	'='	430.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
Cc1cccc(C[C@H](NC(=O)c2ccc(Cl)cc2F)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	2.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC[C@@H](C)[C@H](NC(=O)OC(C)(C)C)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	460.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)OCC1(CCCc2ccccc2)CCC1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	2000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
CCCc1cc(-c2cccc(CC(C)C)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CN1Cc2cc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4C[C@@H](O)CCN4)cc3)ccc2C1=O	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin)
N#CN1CCC(NS(=O)(=O)c2ccccc2)C1	IC50	'='	1400.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
Cc1ccccc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
Cc1nc(C)c(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)s1	IC50	'='	10000.0	nM	Inhibition of cathepsin B
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4ccccc4s3)CC2)CC1	IC50	'='	1584.89	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc(C(F)(F)F)cs3)CC2)CC1	IC50	'='	6309.57	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CC(C)CC(C(=O)NCC#N)c1cccc(-c2cncnc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCCNC(=O)C(=O)[C@H](Cc1ccccc1)NC(=O)C1Cc2cc3c(cc2S(=O)(=O)N1CC)OCCO3	IC50			nM	Inhibitory activity against cathepsin B; In active
NC(=S)N/N=C(/c1cccc(Br)c1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	IC50	'='	1590.0	nM	Inhibition of human liver cathepsin B
COc1ccc2c(c1)/C(=N/NC(N)=S)CCC2	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
Cc1cccc(C[C@H](NC(=O)c2ccc(F)cc2F)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	6.8	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
Cc1cc(C)cc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	11.9	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC(C)(C)NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1	IC50	'='	6457.0	nM	Inhibition of human recombinant cathepsin B by fluorescence assay
CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(=O)NCc1ccccc1	IC50	'='	100000.0	nM	Compound was tested for inhibition of human liver Cathepsin B
CC(C)C[C@@H](CSC1CC(=O)N1C(=O)NCc1ccccc1)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CC(C)(C)C(=O)Nc1ccc2c(c1)C(=O)C(=O)c1ccccc1-2	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(-c2cccnc2)c1)NC(=O)c1ccccc1	IC50	'='	7943.28	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)C(=O)NCc1ccccc1	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
N#CN1CC(OCC2CCCCC2)C1	IC50	'='	500.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
CCCCS(=O)(=O)C[C@@H](NC(=O)OCCNC(C)=O)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	935.0	nM	Inhibition of cathepsin D
CCCCS(=O)(=O)C[C@@H](NC(=O)c1cccnc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	474.0	nM	Inhibition of cathepsin D
CS(=O)(=O)c1ccc2[nH]c3c(c2c1)CN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)CC3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
COc1cc(O)ccc1/C=C/C(=O)c1ccc(NC(C)=O)cc1	IC50	'='	46810.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
COc1ccc(C(=O)/C=C/c2ccc(OC)c(Br)c2)c(O)c1	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
NC(=S)N/N=C1\CCCc2c(O)cccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
COc1cc(O)ccc1C(=O)/C=C/c1ccc(F)cc1	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C	IC50	'>'	3300.0	nM	Inhibition of human Cathepsin B
COc1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)[C@H](C)C2)nc1OC	IC50	'='	1690.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
C[C@@H]1CN(c2ccc3c(c2)OCO3)CCN1C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	645.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
CCCCC(=O)N[C@@H](Cc1cccc(C)c1)C(=O)NCC#N	IC50	'='	3000.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
NC(=S)N/N=C(\c1cccc(O)c1)c1cc(Br)cc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin-B using Z-RR-AMC as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by fluorometric method
CCOC(=O)C(C)=C=C(c1ccccc1)c1ccccc1	IC50	'='	232000.0	nM	Inhibition of cathepsin B in oxygen free condition
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(-c3ccncc3)cc2)c1	IC50	'='	3329.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)C[C@H](Nc1ccc(-c2ccc(N3CCNCC3)cc2)cc1)C(=O)NCC#N	IC50	'='	26.0	nM	Inhibitory concentration against human cathepsin B
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4ccncc4s3)CC2)CC1	IC50	'='	3981.07	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CC(C)C[C@H](NC(=O)OCC(C)(C)Oc1ccc(F)cc1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O	IC50	'='	1900.0	nM	Inhibition of human Cathepsin B
Cc1cccc(C[C@H](NC(=O)c2ccc(F)cc2F)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	180.0	nM	Competitive inhibition of human cathepsin B using Z-RR-AMC as substrate assessed as inhibition constant preincubated for 20 mins followed by pre-activated enzyme addition and measured after 15 mins by Cheng-Prusoff equation analysis
CC(C)C[C@H](NC(=O)OCC(C)(C)Sc1ccccc1)C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O	IC50	'='	2600.0	nM	Inhibition of human Cathepsin B
NC(=S)NN=C(c1ccc(Br)cc1)c1ccc(Br)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)[C@@H](C)CC	IC50	'='	3.7	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
NC(=S)N/N=C(\c1ccccc1)c1cccc(C(=O)c2ccccc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
COc1ccc(C(=O)NCC(=O)NC/C=C/S(C)(=O)=O)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1	IC50	'>'	100000.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
COc1ccc(OC)c(S(=O)(=O)N[C@@H]2C[C@H](C)N(C#N)C2)c1	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
N#CCNC(=O)[C@H](Cc1ccccc1)NC(=O)C(c1ccccc1)c1ccccc1	IC50	'='	496.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CCCC[C@H](NC(=O)OCC(C)(C)Cc1ccccc1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	5000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
CC(C)C[C@H](Nc1ccccc1-c1ccc(N2CCNCC2)cc1)C(=O)NCC#N	IC50	'='	1812.0	nM	Inhibitory concentration against human cathepsin B
CCC(C)CNc1nc(C#N)nc2c1ncn2C1CCCC1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
COc1ccc(Cn2cnc3c(NCc4ccccc4)nc(C#N)nc32)cc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CC[C@H](NC(=O)N1C(=O)CC1SC[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CS(=O)(=O)N1CCC[C@@H]1C(=O)N[C@H](C=O)Cc1ccccc1	IC50	'='	3000.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
O=C1NN(c2ccc(Cl)cc2)C(=O)/C1=C\c1ccc(-c2ccc(C(=O)O)cc2)o1	IC50	'='	81500.0	nM	Inhibition of human cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	23000.0	nM	Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(=O)NC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	51000.0	nM	Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	18000.0	nM	Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CC(=O)OCc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C/C=C/c1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
C[C@@H](NC(=O)N1C(=O)CC1SCc1ccccc1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CC(C)C(NC(=O)OC(C)(C)C)C(=O)N1CCCCN1C#N	IC50	'='	38.0	nM	Inhibition of human recombinant cathepsin B
CC(C)C(Nc1cccc(C#N)c1)C(=O)N1CCCCN1C#N	IC50	'='	40.0	nM	Inhibition of human recombinant cathepsin B
Cc1cccc(C[C@H](Nc2ccccc2)C(=O)N[C@H](C#N)COCc2ccc(C(=O)O)cc2)c1	IC50	'='	282.0	nM	Inhibitory activity against cathepsin B (catB)
N#Cc1nc(NCc2cccc(-c3cn(S(=O)(=O)c4ccccc4)c4ccccc34)c2)c2ncn(CCCO)c2n1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2cccc(-c3ccc4ccccc4c3)c2)c2ncn(CCCO)c2n1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)c(Cl)c2)c2ncn(CCO)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
COc1ccc(CNc2nc(C#N)nc3c2ncn3Cc2ccccc2)cc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCn1cnc2c(NCc3ccccc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CC[C@@H](C)[C@H](NC(=O)NC(C)C)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	580.0	nM	Inhibition of human cathepsin B
CCOC(=O)/C=C/C=C/C(=O)[C@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)N1CCOCC1	IC50	'='	2250.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
Cc1ccc(S(=O)(=O)N2C[C@H](N=[N+]=[N-])C[C@H]2C(=O)N[C@H](C=O)Cc2ccccc2)cc1	IC50	'>'	10000.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	IC50	'='	11000.0	nM	Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate by spectrofluorometer analysis
	IC50	'='	600.0	nM	Inhibitory concentration against human liver cathepsin B
Cc1cccc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)c1C	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1cccc2ccccc12	IC50	'='	10000.0	nM	Inhibition of cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1cccc2c1CCCC2	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1ccnc2ccccc12	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(-c2nnco2)c1)NC(=O)c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(-c2nncs2)c1)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(C)C[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'>'	1000.0	nM	Inhibition of human cathepsin B
Cc1cccc(O[C@@H]2CCNC[C@H]2O)c1C	IC50	'>'	100000.0	nM	Inhibition of human recombinant cathepsin B
COc1ccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2ccccc2)C(=O)O)cc1	IC50	'='	97.7	nM	Compound was tested for its inhibitory activity against cathepsin B
COc1cc(/C=C/C(=O)c2ccco2)ccc1O	IC50	'='	20590.0	nM	Inhibition of human liver cathepsin B using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(-c3ccc(S(C)(=O)=O)cc3)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	1873.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccsc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	1155.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccncc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	2374.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	6984.0	nM	Inhibition of Cathepsin B
CSc1ccc(-c2ccc([C@H](N[C@@H](CC(C)C)C(=O)NCC#N)C(F)(F)F)cc2)cc1	IC50	'='	1400.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccccc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	1605.0	nM	Inhibition of Cathepsin B
CCCCC(=O)N[C@@H](Cc1cccc(C)c1)C(=O)N[C@H](C#N)COCc1cccc(C(=O)O)c1	IC50	'='	35.7	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
Cc1ccc2oc(C(=O)C(C)NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)nc2c1	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
O=C[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	85.1	nM	Inhibitory activity against Cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)C(=O)Nc1ccccn1	IC50	'='	107000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
O=C[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCc1ccccc1	IC50	'>'	1000.0	nM	Inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@H](Cc2ccccc2)NC(=O)C2CCN(C(=O)OCc3ccccc3)CC2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
COc1ccc(Nc2nc(C#N)nc(N3CCNCC3)n2)cc1	IC50	'='	45.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CCCCNC(=O)C(=O)[C@H](CC)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1	IC50	'='	354.1	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
NC(=S)N/N=C1\CCS(=O)(=O)c2ccc(OC(F)(F)F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
Cc1cccc(C[C@H](Nc2ccccc2)C(=O)N[C@H](C#N)COCc2ccccc2)c1	IC50	'='	194.0	nM	Inhibitory activity against cathepsin B (catB)
COc1ccc(CC(NC(=O)c2ccc(-c3ccccc3)cc2)C(=O)NC2(C#N)CC2)cn1	IC50	'='	4080.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(\c1ccc(Cl)cc1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CCCC(C)NC(=O)C(=O)[C@H](CC)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1	IC50	'='	349.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(O[C@@H](C)C(F)(F)F)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	223.8	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	43.3	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)C(Nc1cccc(C(F)(F)F)c1)C(=O)N1CCCCN1C#N	IC50	'='	23.0	nM	Inhibition of human recombinant cathepsin B
CCOc1cccc2c3c([nH]c12)CCN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)C3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
Cc1cccc(C[C@H](NC(=O)c2ccc(Cl)c(Cl)c2)C(=O)NCC#N)c1	IC50	'='	31.3	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CCNC(=O)C(=O)[C@H](CC)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1	IC50	'='	112.3	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Br)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	98.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
S=C(NCc1ccccc1)NN=C(c1cccc(Br)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCCc2ccccc2)nc(N2CCNCC2)n1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(O[C@@H](C)C(F)(F)F)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	335.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCNC(=N)N	IC50	'='	117.0	nM	Compound was tested for its inhibitory activity against cathepsin B
O=C(O)CNC(=O)c1ccc2c(c1)C(=O)C(=O)c1ccccc1-2	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
COC(=O)CCC(=O)Nc1cccc2c1C(=O)C(=O)c1ccccc1-2	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
O=C[C@H](Cc1c[nH]c2ccccc12)NC(=O)C1CCCCC1	IC50	'='	780.0	nM	Inhibition of human cathepsin B
CCC(NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(=O)C1CCCCC1)C(=O)c1nc2ccccc2o1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin-B
CC(=O)N1C[C@H](S(=O)(=O)c2ccccc2Cl)C[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	47600.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CCC(NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(=O)c1ccccc1)C(=O)c1nc2ccccc2o1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin-B
CC(C)C(Nc1cccc(Cl)c1)C(=O)N1CCCCN1C#N	IC50	'='	32.0	nM	Inhibition of human recombinant cathepsin B
CCCC[C@@H](C=O)NC(=O)OC1(Cc2ccccc2)CCCCC1	IC50	'='	12000.0	nM	Inhibitory concentration against recombinant human cathepsin B was determined in a fluorescence assay using 10 uM Cbz-Phe-Arg-AMC as substrate
N#CCNC(=O)C1(NC(=O)c2ccc(-c3csc(N4CCOCC4)n3)cc2)CCCCC1	IC50	'='	4200.0	nM	Inhibitory activity against human cathepsin B
COc1ccc(C(=O)c2cccc(/C(=N/NC(N)=S)c3ccc(O)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
CC(=O)c1c(Nc2ccc(Cl)cc2)[nH]c2c(Cl)cc([N+](=O)[O-])cc2c1=O	IC50	'='	14.2	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CC(=O)c1c(Nc2ccc(Cl)cc2)[nH]c2c(Br)ccc(Cl)c2c1=O	IC50	'='	1530.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@@H](C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	59.0	nM	Inhibition of human recombinant cathepsin B
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(Cl)cc2C)CN1C(=O)OC(C)(C)C)C(=O)C(=O)NC1CC1	IC50	'='	22623.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#Cc1nc(NCc2cccc(-c3cc(Cl)cc(Cl)c3)c2)c2ncn(CCCO)c2n1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
CN1CCC(CCOc2ccc(-c3cc4c(ncn4C)c(C#N)n3)cc2C(F)(F)F)CC1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1ccc(Br)s1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2cccnc2)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	79.0	nM	Inhibition of human recombinant cathepsin B
CCCC[C@H](NC(=O)OC1(Cc2ccccc2)CCCC1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	12000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccc(C#N)cc1F	IC50	'='	9.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@@H](C#N)Cc1ccc(C#N)cc1F	IC50	'='	260.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	433.0	nM	Inhibition of human Cat B in HepG2 cells
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	5000.0	nM	Inhibition of human liver cathepsin B pre-incubated for 24 hrs in non-buffer solution without DTT
Cc1cccc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)c1	IC50	'='	5011.87	nM	Inhibition of cathepsin B
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(-c2nnc(CCN)o2)c1)C(=O)NCC#N	IC50	'='	6309.57	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
O=C(/C=C/c1ccc(O)c2ccccc12)c1ccc(O)cc1O	IC50	'='	12950.0	nM	Inhibition of cathepsin B in human SH-SY5Y cells using RR-AMC as substrate by fluorescence microplate reader assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3Cl)CN2C(=O)C2CCCCC2)CC1	IC50	'='	14900.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
COc1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)cc1	IC50	'='	1440.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#CCNC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCN(c2ccccc2)CC1	IC50	'='	455.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#CC1(NC(=O)[C@H](Cc2cscn2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'='	2371.0	nM	Inhibition of human cathepsin B
N#CC1(NC(=O)[C@H](Cc2ccccc2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'='	2210.0	nM	Inhibition of human cathepsin B
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCNCC2)CC1	IC50	'='	13300.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CN1CCN(C(=O)[C@@H]2C[C@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)NC2(C#N)CC2)CC1	IC50	'='	6400.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CC1CCN(C(=O)[C@@H]2C[C@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)NC2(C#N)CC2)CC1	IC50	'='	700.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
NC(=S)N/N=C(/c1cccc(Br)c1)c1cccc(Br)c1O	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
COC(=O)CCCCCCC(=O)Nc1ccc2c(c1)C(=O)C(=O)c1ccccc1-2	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)C1CCCCC1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CCCc1cc(-c2cccc(C(C)=O)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2ccc(Cl)c(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2C(F)(F)F)CN1c1ccccc1[N+](=O)[O-])C(=O)c1nc2ccccc2o1	IC50	'='	105500.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
NC(=S)N/N=C(\c1cccc(Cl)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCCS(=O)(=O)[C@@H]12)OCc1ccccc1	IC50	'>'	50000.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
CC(C)CC(NC(=O)c1cccc(-c2ccc(S(C)(=O)=O)cc2)c1)C(=O)N(C)N(C)C#N	IC50	'='	3366.0	nM	Inhibition of human liver cathepsin B
CCCCS(=O)(=O)CC(NC(=O)OCCC#N)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	205.0	nM	Inhibition of cathepsin D
CCCCS(=O)(=O)C[C@@H](NC(=O)OC)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	171.0	nM	Inhibition of cathepsin D
CC(C)Oc1c(Br)cccc1-c1cccc(CNc2nc(C#N)nc3c2ncn3CCCO)c1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(\c1ccc(Br)cc1)c1cccc(/C(=N/NC(N)=S)c2ccc(Br)cc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
N#CN1CC(CNC(=O)C2CCCCC2)C1	IC50	'='	150.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(=O)NCc1ccccc1	IC50	'='	172000.0	nM	Compound was tested for inhibition of human liver Cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1cc(F)c(F)c(F)c1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CC[C@H](NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1N[C@H]1C(=O)O)C(=O)N[C@H](/C=C/C(=O)O)CCCN=C(N)N	IC50	'='	1.4	ug.mL-1	Inhibition of cathepsin B
CS(=O)(=O)N1CCC[C@H]1C(=O)N[C@H](C=O)Cc1ccccc1	IC50	'='	883.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
NC(=S)N/N=C(/c1cccc(Br)c1)c1cccc(F)c1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(-c2ccnnc2)c1)NC(=O)c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(C3(C(=O)N4CCOCC4)CC3)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	64.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(-c3ccncc3)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	54.0	nM	Inhibition of human Cat B in HepG2 cells
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	1400.0	nM	Inhibition of human liver cathepsin B pre-incubated for 2 hrs in buffer without DTT
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(F)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	83.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#Cc1nc(NCc2cccc(-c3ccccc3C(F)(F)F)c2)c2ncn(CCCO)c2n1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
COC(=O)c1cccc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)c1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
COc1ncc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)c(OC)n1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
Cn1nccc1-c1cccc(C[C@H](NC(=O)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	7943.28	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
N#CC1(NC(=O)[C@H](Cc2ccccn2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'>'	5000.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)CNc1cccc(F)n1	IC50	'='	68.0	nM	Inhibition of human recombinant cathepsin B
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NC1CC1	IC50	'='	417.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
Cc1ccc(S(=O)(=O)N2C[C@H](C#N)C[C@H]2C(=O)N[C@H](C=O)Cc2ccccc2)cc1	IC50	'='	8700.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(N3CCOCC3)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	101.1	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCS(=O)(=O)[C@H]12)OCc1ccccc1	IC50	'='	6010.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
O=C1O[C@@H]2CN1CC[C@@H]2Oc1ccccc1	IC50	'='	5.0	nM	Inhibition of human recombinant cathepsin B
CC(C)CC(NC(c1ccc(-c2ccc(N3CCNCC3)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibitory activity against cathepsin B from human
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1cccc(Cl)c1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	271.0	nM	Inhibition of cathepsin D
NC(=S)N/N=C(/c1ccc(Br)cc1)c1ccccc1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(/c1ccc(Br)cc1)c1ccc(C(F)(F)F)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CCC(CC)NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1	IC50	'='	2340.0	nM	Inhibition of human recombinant cathepsin B by fluorescence assay
C[C@]12CCCO[C@@H]1[C@]1(COC(N)=N1)c1cc(-c3cncc(Cl)c3)ccc1O2	IC50	'='	110000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(C)C[C@H](N[C@@H](c1ccc(-c2cccc3[nH]ccc23)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	4699.0	nM	Inhibition of Cathepsin B
Cc1cccc(C[C@H](Nc2ccccc2)C(=O)N[C@H](C#N)COCc2ccc(F)c(C(=O)O)c2)c1	IC50	'='	12.2	nM	Inhibitory activity against cathepsin B (catB)
N#CCNC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccccc1	IC50	'='	940.0	nM	Inhibitory activity against human cathepsin B expressed in HepG2 cells
NC(=S)N/N=C(/c1cc(Cl)cc(Cl)c1)c1cccs1	IC50	'='	300.0	nM	Inhibition of human cathepsin B
COc1ccc(C(=O)NCc2ccnc(C#N)n2)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1	IC50	'='	8100.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccncc1	IC50	'='	79.0	nM	Inhibition of human Cat B in HepG2 cells
[N-]=[N+]=CC(=O)[C@H](Cc1ccc(I)cc1)NC(=O)CN	IC50	'='	2940.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
COc1ccc(S(=O)(=O)n2nc(OC(=O)c3cccs3)cc2N)cc1	IC50	'='	690.0	nM	Inhibition of human liver cathepsin B
Cc1ccc(S(=O)(=O)n2nc(OC(=O)c3ccco3)cc2N)cc1	IC50	'='	1750.0	nM	Inhibition of human liver cathepsin B
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccc(F)cc1	IC50	'='	440.0	nM	Inhibition of human liver cathepsin B
COCCCn1cnc2c(NCc3ccc(Cl)c(Cl)c3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)c(Cl)c2)c2ncn(CCCO)c2n1	IC50	'='	5430.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(CCCCO)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccccc2)c2ncn(Cc3cccc(C(F)(F)F)c3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCn1cnc2c(NCc3ccc(C)cc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
Cc1cccc(CNc2nc(C#N)nc3c2ncn3CC2CCCCC2)c1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
COc1ccc(CNc2nc(C#N)nc3c2ncn3C2CCCC2)cc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NC2CCCCC2)c2ncn(Cc3ccccc3)c2n1	IC50	'='	17700.0	nM	Inhibition of human liver cathepsin B
CC(=O)N[C@@H](CCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'>'	150000.0	nM	Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1ccccc1	IC50	'='	5011.87	nM	Inhibition of cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2cccc(Br)c2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	6629.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)O[C@H](CN1CCN(c2ccc(C(F)(F)F)cc2)C1=O)C(C)(C)C)C(=O)C(=O)Nc1ccn[nH]1	IC50	'='	60000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
Cc1cc(C)cc(CC(NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	40.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	122.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)CCc1ccccc1	IC50	'='	397.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)[C@H](N[C@@H](c1ccc(-c2ccc(C3(C(N)=O)CC3)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccc(C#N)cc1F	IC50	'='	41.0	nM	Inhibition of human Cat B in HepG2 cells
NC(=S)N/N=C(/c1cccc(Br)c1)c1cccc(OP(=O)([O-])[O-])c1.[Na+].[Na+]	IC50				Inhibition of human liver cathepsin-B using Z-RR-AMC as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by fluorometric method
NC(=S)N/N=C(\c1cccc(Br)c1)c1cc(O)cc(C(=O)c2cccc(Br)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CN1CCN(c2nc(-c3ccc(C(=O)NC4(C(=O)NCC#N)CCCCC4)cc3)cs2)CC1	IC50	'='	1100.0	nM	Inhibitory activity against human cathepsin B
CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1	IC50	'='	61.0	nM	Inhibitory activity against human cathepsin B expressed in HepG2 cells
C[C@H](NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)C(F)(F)C(=O)NCc1ccccc1	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
C[C@@H](NC(=O)N1C(=O)CC1SCCc1ccccc1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CCCCNC(=O)C(=O)[C@H](CCC)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1	IC50	'='	29.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
NC(=S)N/N=C1\CC(Nc2ccccc2)c2ccc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
N#CN1CC(OCc2ccccc2)C1	IC50	'='	500.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
NC(=S)N/N=C(\Cc1ccccc1)c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
N#Cc1nc(NCc2cccc(-c3ccc4[nH]ccc4c3)c2)c2ncn(CCCO)c2n1	IC50	'='	13000.0	nM	Inhibition of human liver cathepsin B
CC(C)c1ccccc1-c1cccc(CNc2nc(C#N)nc3c2ncn3CCCO)c1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
Cc1cccc(C[C@H](Nc2ccc3c(c2)C(=O)OC3)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	6.5	nM	Inhibitory activity against cathepsin B (catB)
N#Cc1nc(Nc2ccc(OC(F)(F)F)cc2)nc(N2CCOCC2)n1	IC50	'>'	500000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CN1Cc2cc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CCCCN4)cc3)ccc2C1=O	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin)
C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCOCC2)ccc1C	IC50	'='	3000.0	nM	Inhibition of recombinant human C-terminal polyhistidine-tagged cathepsin B (Arg18 to Ile339 residues) expressed in HEK293 cells using Z-Leu-Arg-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins
CC[C@@H](C)[C@H](/N=C(\S)Nc1ccccc1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	440.0	nM	Inhibition of human cathepsin B
CN(C)CCOc1ccc(C(=O)NCC(=O)NCC#N)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1	IC50	'>'	100000.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
NC(=S)N/N=C1\CCNc2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CCN1C(C(=O)N[C@@H](Cc2ccccc2)C(=O)C(=O)NCCNS(=O)(=O)c2ccc(-c3ccccn3)s2)Cc2cc3c(cc2S1(=O)=O)OCCO3	IC50			nM	Inhibitory activity against cathepsin B
C[C@@H](NC(=O)N1C(=O)CC1SCc1ccc(CC(=O)OC(C)(C)C)cc1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CC(C)CC(NC(=O)c1ccccc1)C(=O)NCC#N	IC50	'='	1903.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(CC(C)(C)N)CC3)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
N#Cc1nc(Nc2ccc([N+](=O)[O-])cc2)nc(N2CCOCC2)n1	IC50	'='	60000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
N#CN1CC(CNS(=O)(=O)c2ccccc2)C1	IC50	'='	300.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
CCOC(=O)/C=C/C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	50.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CC(=O)CN1CCN(c2ccc(-c3cccc(C(CC(C)C)C(=O)NCC#N)c3)cc2)CC1	IC50	'='	550.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CN1CCN(c2ccc(-c3cccc(C(Cc4ccccc4)C(=O)NCC#N)c3)cc2)CC1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCO[C@H]12	IC50	'>'	50000.0	nM	In vitro Inhibitory activity against Cathepsin B cysteine protease by using Cbz-Phe-Arg-AMC
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCNCC3)cc2)c1	IC50	'='	2405.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(C)CC3)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)OCc1ccccc1	IC50	'>'	1000000.0	nM	Compound was tested for inhibition of human liver Cathepsin B
CN(CCc1cnc[nH]1)c1cnc2[nH]c(=O)[nH]c(=O)c2n1	IC50	'='	1.4	ug.mL-1	Inhibition of cathepsin B (unknown origin) assessed as reduction in enzyme activity
O=C1C(=O)c2cccnc2-c2ccccc21	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
O=C[C@H](Cc1ccccc1)NC(=O)[C@@H]1C[C@@H](OS(=O)(=O)c2ccccc2)CN1S(=O)(=O)c1ccccc1	IC50	'='	38.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
O=C[C@H](Cc1c[nH]c2ccccc12)NC(=O)OCc1ccccc1	IC50	'>'	1000.0	nM	Inhibition of human cathepsin B
O=C[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NS(=O)(=O)c1cccc2ccccc12	IC50	'='	3900.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](Nc2ccccc2)C(=O)N[C@H](C#N)COCc2ccc(Cl)c(C(=O)O)c2)c1	IC50	'='	8.7	nM	Inhibitory activity against cathepsin B (catB)
NC(=S)N/N=C(\c1ccc(Br)cc1)c1cccc(C(=O)c2ccc(Br)cc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
NC(=S)N/N=C(\c1ccc(O)cc1)c1cccc(C(=O)c2ccc(O)cc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CC(C)C(NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NC1CCCCC1	IC50	'='	52.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
Cc1cccc(C[C@H](NC(=O)c2cc(C(C)(C)C)nn2C)C(=O)NCC#N)c1	IC50	'='	3981.07	nM	Inhibition of cathepsin B
CCc1cc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)n(C)n1	IC50	'='	7943.28	nM	Inhibition of cathepsin B
COC(=O)c1ccccc1-c1cccc(CNc2nc(C#N)nc3c2ncn3CCCO)c1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	3200.0	nM	Inhibition of human liver cathepsin B pre-incubated for 24 hrs in buffer without DTT
NC(=S)N/N=C1\CCS(=O)(=O)c2ccc(N)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CCCC[C@@H](C#N)n1cc([C@@](C)(NC(=O)c2ccccc2)C2CCCCC2)nn1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CC(=O)N[C@@H](CCC(=O)OCc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
CC(C)(C)[C@H](NC(=O)Cc1cc(Cl)cc(Cl)c1)C(=O)NCC(=O)NC/C=C/S(C)(=O)=O	IC50	'>'	100000.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
COc1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NCC#N)CC2)cc1OC	IC50	'='	1270.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
C[C@H](C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC(C#N)(C1CC1)C1CC1)C(F)(F)F	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC(C#N)(C1CC1)C1CC1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CCCCS(=O)(=O)C[C@@H](NC(=O)c1cc(C)[nH]n1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	341.0	nM	Inhibition of cathepsin D
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1ccc(OC)cc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	320.0	nM	Inhibition of cathepsin D
CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4cccc(C(F)(F)F)c4)n3)nc2)CC1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate pretreated for 60 mins followed by substrate addition incubated for 30 mins
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1ccc(F)c(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
Cc1cccc2c3c([nH]c12)CCN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)C3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCC2)ccc1C	IC50	'='	3000.0	nM	Inhibition of recombinant human C-terminal polyhistidine-tagged cathepsin B (Arg18 to Ile339 residues) expressed in HEK293 cells using Z-Leu-Arg-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins
O=C1O[C@H]2CN1CC[C@@H]2Br	IC50	'='	158.0	nM	Inhibition of human recombinant cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCS(=O)(=O)[C@@H]12)OCc1ccccc1	IC50	'='	350.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
NC(=O)c1cn(-c2ccc(O)cc2)c2cc(-c3ccncc3)ccc2c1=O	IC50	'='	32000.0	nM	In vitro inhibitory activity against Cathepsin B
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N1Cc2ccccc2C1=O)C(C)(C)C)C(=O)C(=O)NCc1ccccc1	IC50	'='	429.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NCc1ccccc1	IC50	'='	512.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NCc1ccc(C(F)(F)F)cc1	IC50				Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CS(=O)(=O)c1ccc2c(c1)/C(=N/NC(N)=S)CCS2(=O)=O	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCc2ccc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
COc1ccc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)cc1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2cccc(-c3cccs3)c2)c2ncn(CCCO)c2n1	IC50	'='	2500.0	nM	Inhibition of human liver cathepsin B
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	250.0	nM	Inhibition of human liver cathepsin B
CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCO[C@H]12	IC50	'='	30000.0	nM	In vitro Inhibitory activity against Cathepsin B cysteine protease by using Cbz-Phe-Arg-AMC
N#CCNC(=O)[C@H](Cc1cccc(-c2cccnn2)c1)NC(=O)c1ccccc1	IC50	'='	6309.57	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
NC(=S)N/N=C1\CCS(=O)(=O)c2ccc(Cl)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCCS(=O)(=O)c2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)NN=C1c2cc([N+](=O)[O-])ccc2-c2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCCc2cc(N)ccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
Cc1ccc(/C(=N/NC(N)=S)c2ccccc2)cc1	IC50	'='	13000.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(\CCc1ccccc1)c1cc(Cl)cc(Cl)c1	IC50	'='	4900.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(\CCc1ccccc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	IC50	'='	3000.0	nM	Inhibition of human cathepsin B
N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3CCCCN3)cc2)cc1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin)
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CC3CCC(C2)O3)CC1	IC50	'='	13100.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
C[C@@H]1CN(c2ccccc2)CCN1C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	649.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
C[C@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	3430.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
Cc1cccc(C[C@H](NC(=O)c2ccc(Cl)cc2F)C(=O)N[C@H](C#N)COCc2ccccc2)c1	IC50	'='	16.9	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
N#CCNC(=O)[C@H](Cc1ccccc1)NC(=O)Cc1ccccc1	IC50	'='	34000.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
N#Cc1nc(Nc2ccc(C(F)(F)F)cc2)nc(N2CCNCC2)n1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3C(F)(F)F)CN2)CC1	IC50	'>'	25000.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCC2)CC1	IC50	'='	39400.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCCC2)CC1	IC50	'='	7100.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCS(=O)(=O)CC2)CC1	IC50	'='	38000.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CCN[C@H](C(=O)N[C@H](C(=O)NCC(=O)NC/C=C/S(C)(=O)=O)C(C)(C)C)c1cc(Cl)cc(Cl)c1	IC50	'>'	100000.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
N#Cc1nc(Nc2ccc(C(F)(F)F)cc2)nc(NC2CCCCC2)n1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
Cc1cccc(CNc2nc(C#N)nc(NC3CCCCC3)n2)c1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
N#Cc1nc(Nc2ccc([N+](=O)[O-])cc2)nc(N2CCNCC2)n1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CC(C)(C)[Si](C)(C)Oc1cccc(/C(=N\NC(N)=S)c2cccc(Br)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
COc1cc(OC)cc(/C(=N\NC(N)=S)c2cccc(Br)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin-B using Z-RR-AMC as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by fluorometric method
NC(=S)N/N=C1\CC[S+]([O-])c2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CC(c2ccccc2)Oc2ccccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
O=C(NC1CC1)C(=O)C1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3Cl)CN2C(=O)C2(c3ccc(Cl)cc3)CC2)CC1	IC50	'='	25000.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](C)[C@@H](C(=O)O[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)/C=C/C(=O)N1C(=O)C=C(OC)[C@@H]1C)N(C)C	IC50	'='	1700.0	nM	Inhibition of human Cathepsin B using Z-Phe-Arg-aminomethylcoumarin as substrate preincubated for 30 mins followed by substrate addition
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCCc1ccc2ccccc2c1	IC50	'='	172.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccnc2ccccc12)C(C)(C)C)C(=O)C(=O)NC1CCCCC1	IC50	'='	628.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
C[C@]12CCCO[C@@H]1[C@]1(CSC(N)=N1)c1cc(-c3cccc(C#N)c3)ccc1O2	IC50	'='	28000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
C[C@]12CCCO[C@@H]1[C@]1(COC(N)=N1)c1cc(-c3cncnc3)ccc1O2	IC50	'>'	200000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NCc1ccc(S(N)(=O)=O)cc1	IC50	'='	984.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CN1C(=O)[C@]2(N=C1N)c1cc(-c3cccnc3F)ccc1O[C@@H]1CCCO[C@H]12	IC50	'='	13000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(C)C[C@H](N[C@@H](c1ccc(Oc2ccccc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCOCC2)CCC1	IC50	'>'	25000.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
Cc1nn(C)c2cc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)[C@H](C)C3)ccc12	IC50	'='	766.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
Cn1c2c(c3c(F)c(F)ccc31)CN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)CC2	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4ccc(F)cc4c3C2)CC1	IC50	'='	3520.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CCNC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCCCC1	IC50	'='	8750.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
O=C(NC1CC1)C(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1	IC50	'='	210.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
Cc1cccc(C[C@H](NC(=O)c2cc(C(C)(C)C)nn2C)C(=O)NCC#N)c1	IC50	'='	3981.07	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(=O)c1c(Nc2ccc(C)cc2Cl)[nH]c2c([N+](=O)[O-])cc(Cl)cc2c1=O	IC50	'='	396.8	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
COc1ccc(C(=O)c2cccc(/C(=N/NC(N)=S)c3ccc(OC)cc3)c2)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CCOC(C)=O	IC50				Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	142.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	170.0	nM	Inhibition of human recombinant cathepsin B
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	45400.0	nM	Inhibition of human liver cathepsin B pre-incubated for 17 hrs in assay buffer with DTT
C[C@]12CCCO[C@@H]1[C@]1(COC(N)=N1)c1cc(-c3cc(F)cc(Cl)c3)ccc1O2	IC50	'='	29000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
C[C@@]12CCCO[C@H]1[C@]1(COC(N)=N1)c1cc(-c3cccnc3F)ccc1O2	IC50	'='	10000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C(=O)O	IC50	'='	45.1	nM	Compound was tested for its inhibitory activity against cathepsin B
CCC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@H](C=O)CC(C)C	IC50	'='	100.0	nM	Inhibition of human cathepsin B
CC(C)C(NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NC1CCOCC1	IC50	'='	311.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)C1CCN(C)CC1)C(C)(C)C)C(=O)C(=O)NCc1ccccc1	IC50	'='	283.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)N[C@H](C(=O)C(=O)NC1CCCCC1)C(C)(C)C	IC50				Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C	IC50	'='	78.0	nM	Inhibitory activity against Cathepsin B
O=C1CC(SCc2ccccn2)N1C(=O)NCCOCc1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
C[C@@H](NC(=O)N1C(=O)CC1SCC(=O)c1ccccc1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
O=C1CC(SCc2ccccn2)N1C(=O)N[C@H](CO)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
Cc1cccc(C[C@H](Nc2cccc(S(C)(=O)=O)c2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	13.3	nM	Inhibitory activity against cathepsin B (catB)
N#CCNC(=O)C1(NC(=O)c2ccc(-c3csc(N4CCOCC4)n3)cc2)CCCCC1	IC50	'='	2900.0	nM	Inhibitory activity against human cathepsin B expressed in HepG2 cells
Cc1ccc2nc(C(=O)C(C)NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)oc2c1	IC50	'='	225000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CC(=O)N1CCN(c2ccc(OCc3cc4cnc(C#N)nc4n3CCC3CCC(F)(F)CC3)cc2)CC1	IC50	'>'	30000.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)COCc2ccccc2)c1	IC50	'='	10.2	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC(C)(C)CN(Cc1ccc(Br)cc1)c1nccc(C#N)n1	IC50				Inhibition of Cathepsin B (unknown origin) assessed as inhibition of AFC release using sequence RR labelled with AFC as substrate by fluorescence based analysis
CC(C)(C)OC(=O)N1CC[C@@H](NS(=O)(=O)c2cccc(Br)c2)C1	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
CC(C)C[C@H](NC(=O)OCC(C)(C)Sc1cccc(Cl)c1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O	IC50	'='	1400.0	nM	Inhibition of human Cathepsin B
Cc1cccc2oc(C(=O)C(C)NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)nc12	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CCCCC#Cc1cc(C(=O)OCC)nc2ccc(OC)cc12	IC50	'='	6860.0	nM	Inhibition of cathepsin B (unknown origin) using Z-FR-AMC as substrate by spectrofluorometric analysis
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C3=CCNCC3)cc2)c1	IC50	'='	554.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
N#CCNC(=O)C1(NC(=O)c2ccc(N3CCOCC3)cc2)CCCCC1	IC50	'='	4400.0	nM	Inhibitory activity against human cathepsin B expressed in HepG2 cells
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)CC#Cc2cccc(C(=O)O)c2)c1	IC50	'='	5.6	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC(C)[C@H](NC(=O)c1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@H](C=O)CCCN=C(N)N)C(C)C	IC50	'='	0.029	ug.mL-1	Inhibitory activity against Cathepsin B was determined
NC(=S)N/N=C(\c1cc(O)cc(O)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin-B using Z-RR-AMC as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by fluorometric method
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)C(=O)Nc1ccn[nH]1	IC50	'='	20.0	nM	Inhibition of human recombinant cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)OCc1ccccc1	IC50	'='	85.1	nM	Compound was tested for its inhibitory activity against cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccccc2F)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	6086.0	nM	Inhibition of Cathepsin B
CC(C)CC(C(=O)N(CC#N)OC(=O)C(F)(F)F)c1cccc(-c2ccncc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(I)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	70.1	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)NC(CC(=O)O)C(=O)CF	IC50	'>'	10000.0	nM	Compound was evaluated for its inhibitory activity against Cathepsin B
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NCc1ccccc1	IC50	'='	120.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)C[C@H](CCSc1ccc2ccccc2c1)C(=O)N[C@H](C=O)CC(C)C	IC50	'='	60.0	nM	Inhibitory activity using cysteine protease, Cathepsin B with Cbz-Phe-Arg-AMC as substrate.
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
Cl.N[C@@H](C(=O)Nc1ccc2nc(SCC(=O)c3ccc4ccccc4c3)sc2c1)c1ccccc1	IC50	'>'	50000.0	nM	Inhibition of human cathepsin B
CC(C)[C@@H](N)C(=O)Nc1ccc2nc(SCC(=O)c3ccc4ccccc4c3)sc2c1.Cl	IC50	'>'	50000.0	nM	Inhibition of human cathepsin B
CCc1ccc2c(c1)/C(=N/NC(N)=S)CCS2(=O)=O	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CC(C)c1ccc2c(c1)/C(=N/NC(N)=S)CCS2(=O)=O	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
C[C@]12CCCO[C@@H]1[C@]1(CSC(N)=N1)c1cc(-c3cncc(Cl)c3)ccc1O2	IC50	'='	58000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NCc1ccccc1	IC50	'='	50.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CCNC(=O)C(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)[C@H](CC(C)C)NC(=O)CCCCC1CCSS1	IC50	'='	120.0	nM	Inhibitory activity against cathepsin B
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@@H](Cc2ccccc2)NC(=O)c2ccncc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CCN1C(C(=O)N[C@@H](Cc2ccccc2)C(=O)C(=O)NCCNS(=O)(=O)c2ccccc2)Cc2cc3c(cc2S1(=O)=O)OCCO3	IC50			nM	Inhibitory activity against cathepsin B; In active
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NCC(=O)N1CCc2ccccc2C1	IC50	'='	511.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)C[C@@H](COC1CC(=O)N1C(=O)NCc1ccccc1)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(I)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	106.8	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#CC1(NC(=O)[C@H](CS(=O)(=O)Cc2c(F)cccc2F)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
N#Cc1nc(NCc2ccc(Cl)c(Cl)c2)c2ncn(CC(O)CO)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccccc2)c2ncn(C3CCCC3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@@H](C)C=O	IC50	'='	480.0	nM	Inhibition of human cathepsin B
CCCC[C@@H](/C=N/NC(=O)N1CCc2ccccc21)NC(=O)OC(C)(C)C	IC50	'='	35000.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
CCN(CC)C(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@@H]1CCCN1C(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
C[C@@H](OCc1ccccc1)[C@@H](C#N)NC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1cccc(-c2cccnc2)c1	IC50	'='	33.1	nM	Inhibition of human cathepsin B at pH 4.5 using Z-Phe-Arg-AMC fluorogenic peptide as substrate preincubated for 2 mins followed by substrate addition and measured for 5 mins by fluorescence assay
C[C@@H](OCc1ccccc1)[C@@H](C#N)NC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1ccc(-c2ccccc2)cc1	IC50	'='	42.3	nM	Inhibition of human cathepsin B at pH 4.5 using Z-Phe-Arg-AMC fluorogenic peptide as substrate preincubated for 2 mins followed by substrate addition and measured for 5 mins by fluorescence assay
CCCc1cc(-c2cccc(CC)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CC[C@@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	530.0	nM	Inhibition of human cathepsin B
N#C[C@]1(NC(=O)[C@@H](N)Cc2ccccc2F)C[C@H]1c1ccccc1.O=C(O)C(F)(F)F	IC50	'>'	3000.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
O=C(N[C@H](C(=O)N[C@@H]1C(=O)N2CCO[C@H]12)c1ccccc1)OCc1ccccc1	IC50	'>'	50000.0	nM	In vitro Inhibitory activity against Cathepsin B cysteine protease by using Cbz-Phe-Arg-AMC
Cc1cccc2nc(C(=O)C(C)NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)oc12	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
N#CCNC(=O)[C@H](CC1CCCCC1)NC(=O)c1ccccc1	IC50	'='	19000.0	nM	Inhibitory activity against human cathepsin B
CN1CC/C(=N\NC(N)=S)c2cc(Br)ccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCNc2ccc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
C[C@@H]1CN(C(=O)[C@@H]2C[C@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)NC2(C#N)CC2)C[C@H](C)O1	IC50	'='	3200.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CN(C)C(=O)[C@@H]1C[C@H](S(=O)(=O)c2ccccc2)C[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	22900.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CCNC(=O)C(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](NC(=O)CCCCC1CCSS1)C(C)C	IC50	'='	100.0	nM	Inhibitory activity against cathepsin B
C[C@H]1C[C@@H](NS(=O)(=O)c2cccc(Br)c2)CN1C#N	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2C(F)(F)F)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	165.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)(C)c1ccc(-c2ccc(S(=O)(=O)N3CCC[C@H]3C(=O)N[C@H](C#N)CC(N)=O)cc2)cc1	IC50	'>'	50000.0	nM	Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC fluorogenic substrate
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N1Cc2ccccc2C1=O)C(C)(C)C)C(=O)C(=O)NCc1ccc(CN(C)C)cc1	IC50	'='	2847.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)c1nc2ccccc2o1	IC50	'='	182.6	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(N3CCOCC3)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	93.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
C[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	399.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CNC(=O)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(C)C	IC50	'='	494.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2C(F)(F)F)CN1c1ccccc1[N+](=O)[O-])C(=O)C(=O)NC1CC1	IC50	'='	3181.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCCc1cccc2ccccc12	IC50	'='	68.8	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc([C@@H](O)C(F)F)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	48.0	nM	Inhibition of human Cat B in HepG2 cells
CS(=O)(=O)c1ccc(-c2ccc([C@H](N[C@@H](CC3CC3)C(=O)N[C@H](C#N)Cc3ccccc3)C(F)(F)F)cc2)cc1	IC50	'='	231.0	nM	Inhibition of human Cat B in HepG2 cells
CS(=O)(=O)c1ccc(-c2ccc([C@H](N[C@@H](CC(Cl)Cl)C(=O)N[C@H](C#N)Cc3ccccc3)C(F)(F)F)cc2)cc1	IC50	'='	383.0	nM	Inhibition of human Cat B in HepG2 cells
CCN(CC)C(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CCN(CC)C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@@H]1CCCN1C(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CCN(CC)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@@H]1CCCN1C(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(Cl)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	154.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)N[C@H](C(=O)C(=O)NC1CCCCC1)C(C)C	IC50	'='	67.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
N#CCNC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCc2[nH]c3ccc(F)cc3c2C1	IC50	'='	1420.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CN(C)C(=O)[C@@H]1CCCC[C@H]1C(=O)NCC#N	IC50	'='	9820.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CCCC[C@@H](/C=N/NC(=O)N1CCOCC1)NC(=O)O[C@@H](C)Cc1ccccc1	IC50	'='	270.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
CCCC[C@@H](C=O)NC(=O)O[C@@H](C)Cc1ccccc1	IC50	'='	460.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
CCN1CCN(CCCOc2ccc(-c3cc4c(ncn4C)c(C#N)n3)cc2C(F)(F)F)CC1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
CC1(C)CN(c2ccc(S(C)(=O)=O)cc2)CCN1C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	3510.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	977.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#Cc1nc(Nc2cccc(OC(F)(F)F)c2)nc(NC2CCNCC2)n1	IC50	'='	1800.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	62.7	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2C(F)(F)F)CN1C(=O)C1(C(F)(F)F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	1852.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(Cl)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	115.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
C/N=c1\nc(-c2ccccc2)n(-c2ccccc2)s1	IC50	'>'	50000.0	nM	Inhibition of human Cathepsin B using Z-RR-AMC as substrate preincubated for 30 mins followed by substrate addition measured for 10 mins by FRET assay
CC(C)CN(CC(=O)N(CC(C)C)NC(=O)OCc1ccccc1)/N=C/c1ccccc1B(O)O	IC50	'>'	1000000.0	nM	Inhibitory concentration against Cathepsin B activity
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccnc2ccccc12)C(C)(C)C)C(=O)C(=O)NCc1ccccc1	IC50	'='	3404.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(N)=O	IC50	'='	20.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NCc1cn[nH]c1	IC50	'='	367.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCc1ccccc1	IC50	'='	31.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@@H](C)[C@H](NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	110.0	nM	Inhibition of human cathepsin B
COc1ccc2c(c1)/C(=N/NC(N)=S)CCS2(=O)=O	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CC(=O)Nc1ccc2c(c1)/C(=N/NC(N)=S)CCS2(=O)=O	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	189.6	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)Oc1ccc(C(=O)c2cccc(/C(=N/NC(N)=S)c3ccc(OC(C)C)cc3)c2)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
O=C(N[C@@H](Cc1cccc(F)c1)C(=O)N[C@@H]1C(=O)N2CCS(=O)(=O)[C@@H]12)OCc1ccccc1	IC50	'='	1000.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
NC(=S)N/N=C(\c1ccccc1)c1cccc(C(O)c2ccccc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
Cc1ccc(S(=O)(=O)N2CC(N=[N+]=[N-])CC2C(=O)N[C@H](C=O)Cc2ccccc2)cc1	IC50	'>'	10000.0	nM	Inhibitory activity against cathepsin B.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Br)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	1229.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2C(F)(F)F)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	424.3	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCN(CC)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@@H]1CCCN1C(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CCN(CC)C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CCN(CC)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
N#CN1CC[C@@H](NC(=O)Nc2ccccc2)C1	IC50	'='	1258.93	nM	Inhibition of human recombinant cathepsin B after 1 hr
CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	IC50	'='	2300.0	nM	Inhibition of human CatB after 60 mins fluorescence assay
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccccc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(S(C)(=O)=O)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C34CCN(CC3)CC4)cc2)c1	IC50	'='	2227.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	459.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
N#Cc1nc(NCc2cccc(-c3ccsc3)c2)c2ncn(CCCO)c2n1	IC50	'='	4000.0	nM	Inhibition of human liver cathepsin B
CC(=O)Nc1cccc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)c1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
CN1C(=O)[C@]2(N=C1N)c1cc(-c3cccnc3F)ccc1O[C@H]1CCCO[C@@H]12	IC50	'='	2400.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
Cc1cccc(C[C@H](Nc2ccc3c(c2)C(=O)OC3(C)C)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	5.3	nM	Inhibitory activity against cathepsin B (catB)
Cc1cccc(C[C@H](NC(=O)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	1900.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(CO)c2)c1	IC50	'='	29.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
COc1ccc(Nc2nc(C#N)nc(NC3CCNCC3)n2)cc1	IC50	'='	3500.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(OCC(F)(F)F)cc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	828.8	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(=O)c1c(Nc2ccc(C(C)(C)C)cc2)[nH]c2c(Cl)cc([N+](=O)[O-])cc2c1=O	IC50	'='	3.11	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CC(C)C[C@H](N[C@@H](c1ccccc1)C(F)(F)F)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B
CC(=O)Oc1cccc(/C(=N\NC(N)=S)c2cccc(Br)c2)c1	IC50	'='	1600.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
NC(=S)N/N=C(/c1cccc(Br)c1)c1cccc(OCc2ccccc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
N#Cc1nc(NCc2cccc(-c3ccco3)c2)c2ncn(CCCO)c2n1	IC50	'='	4700.0	nM	Inhibition of human liver cathepsin B
C=Cc1cccc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)c1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
COC(=O)CCC(=O)Nc1ccc2c(c1)C(=O)C(=O)c1cc(NC(=O)CCC(=O)OC)ccc1-2	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)C1CCCCC1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CCCC[C@H](NC(=O)OCC(C)(C)c1ccccc1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	5000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
C[C@@H](NC(=O)C(=O)[C@H](CCCCNC(=O)N1CCOCC1)NC(=O)OCC1(Cc2ccc(F)cc2)CCC1)c1ccccc1	IC50	'>'	5000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
CC(C)C[C@H](N[C@@H](c1ccc(C(=O)c2ccccc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(-c3ccncc3)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	483.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	5239.0	nM	Inhibition of Cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(=O)NC(C)(C)CC)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)CNC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCc1ccccc1	IC50	'>'	150000.0	nM	Inhibition of cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)C(=O)OC(C)(C)C)NC(=O)OCc1ccccc1	IC50				Inhibition of cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NS(=O)(=O)c1ccccc1	IC50				Inhibition of cathepsin B
COCOCCn1cnc2c(NCc3ccc(Cl)c(Cl)c3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)c(Cl)c2)c2ncn(Cc3ccccc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
O=C(c1ccccc1O)c1ccc(O)cc1O	IC50	'='	198000.0	nM	Inhibition of cathepsin B by spectrofluorimetry
NC(=S)N/N=C(\c1cc(F)cc(F)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1cc(F)c(F)c(F)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#CN1CCC(NC(=O)c2ccc(-c3ccccc3)cc2)C1	IC50	'='	300.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
O=C[C@H](Cc1c[nH]c2ccccc12)NC(=O)C(Cc1ccccc1)Cc1ccccc1	IC50	'>'	1000.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](Nc2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	49.0	nM	Inhibitory activity against cathepsin B (catB)
N#CN1CCCC1	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
N#CN1CC[C@@H](NC(=O)c2ccc(F)cc2)C1	IC50	'='	3981.07	nM	Inhibition of human recombinant cathepsin B after 1 hr
Cc1nnc(CN2CCC(CCOc3ccc(-c4cc5c(ncn5C)c(C#N)n4)cc3C(F)(F)F)CC2)o1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
CC(=O)N1CCC(CCOc2ccc(-c3cc4c(ncn4C)c(C#N)n3)cc2C(F)(F)F)CC1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
CCCCS(=O)(=O)C[C@@H](NC(=O)OCC(F)(F)F)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	19.0	nM	Inhibition of cathepsin D
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	5239.0	nM	Inhibition of cathepsin B
CS(=O)(=O)c1ccc(-c2ccc([C@H](N[C@@H](CC(F)(F)F)C(=O)NC(C#N)(C3CC3)C3CC3)C(F)(F)F)cc2)cc1	IC50	'='	434.0	nM	Inhibition of cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC(C#N)c1ccccc1	IC50	'='	3453.0	nM	Inhibition of cathepsin B
O=C(/C=C/c1ccco1)C(C(=O)/C=C/c1ccco1)=C1SCCCS1	IC50	'='	26900.0	nM	Inhibition of human cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)CF)OCc1ccccc1	IC50	'='	680.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
C=Cc1ccc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)cc1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2cccc(-c3ccccc3)c2)c2ncn(CCCO)c2n1	IC50	'='	8400.0	nM	Inhibition of human liver cathepsin B
CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCN=C(N)N	IC50	'='	10.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
CCCC(C)NC(=O)C(=O)[C@H](CCC)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1	IC50	'='	245.9	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)=CC[C@H]1C[C@@]2(CC=C(C)C)C(=O)C(C(=O)c3ccccc3)=C(O)[C@](C=C(C)C)(C2=O)C1(C)C	IC50	'='	73700.0	nM	Inhibition of cathepsin B by spectrofluorimetry
CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N	IC50	'='	6100.0	nM	Inhibition of cathepsin B
CC(C)C[C@H](NC(=O)OCC(C)(C)Sc1ccccc1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)C(=O)NC1CC1	IC50	'='	2000.0	nM	Inhibition of human Cathepsin B
[2H]C([2H])(OC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O)C(C)(C)Sc1ccccc1	IC50	'='	2000.0	nM	Inhibition of human Cathepsin B
N#Cc1nc(NCc2ccc(F)cc2)c2ncn(CCCCO)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCn1cnc2c(NCCc3ccccc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(C3CCCC3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CC(Nc1nc(C#N)nc2c1ncn2Cc1ccccc1)c1ccccc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCCCNc1nc(C#N)nc2c1ncn2CC1CCCCC1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
Cc1ccc(C)c(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)c1	IC50	'='	5011.87	nM	Inhibition of cathepsin B
C[C@@H](NC(=O)N1C(=O)CC1SCc1ccncc1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(-c2nncs2)c1)NC(=O)c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4cc(F)ccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
C[C@@H](C#N)NC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCc2[nH]c3ccc(F)cc3c2C1	IC50	'='	73500.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4c(Cl)cccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4cccc(F)c4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1cccc(Cl)c1	IC50	'='	3981.07	nM	Inhibition of cathepsin B
Cc1cc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)n(C)n1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
Cc1ccc(CNc2nc(C#N)nc3c2ncn3CCCO)cc1	IC50	'='	7690.0	nM	Inhibition of human liver cathepsin B
C[C@H](NC(=O)O[C@H](Cn1cnc2cc(Cl)c(Cl)cc21)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	71.0	nM	Inhibition of human recombinant cathepsin B
C[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	310.0	nM	Inhibition of human recombinant cathepsin B
N#CC1(NC(=O)C(Cc2ccc(Cl)nc2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'>'	5000.0	nM	Inhibition of human cathepsin B
N#CC1(NC(=O)[C@H](CCCCCN)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50				Inhibition of human cathepsin B
CC(C)C[C@H](NCC(F)(F)F)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B
N#CN1CCC(NC(=O)OCc2ccccc2)C1	IC50	'='	200.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
COC(=O)c1cccc(COC[C@@H](C#N)NC(=O)[C@H](Cc2cccc(C)c2)NC(=O)C(c2ccccc2)c2ccccc2)c1	IC50	'='	47.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
[N-]=[N+]=CC(=O)[C@H](Cc1ccccc1)NC(=O)CN	IC50	'>'	30000.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
C[C@@H](NC(=O)N1C(=O)CC1SCc1cccnc1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CCCc1cc(-c2ccc(C(F)(F)F)cc2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2cccc(Br)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
NC(=S)N/N=C1\CCSc2cc(F)c(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
COc1ccc2c(c1)/C(=N/NC(N)=S)CCS2	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCS(=O)(=O)c2c(F)cc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C(/c1ccccc1)c1ccccc1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)NN=C(c1cccc(F)c1)c1cccc(F)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#CN1CC[C@H](NS(=O)(=O)c2ccccc2)C1	IC50	'='	3981.07	nM	Inhibition of human recombinant cathepsin B after 1 hr
CN(C)C(=O)CN1CCC(CCOc2ccc(-c3cc4c(ncn4C)c(C#N)n3)cc2C(F)(F)F)CC1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
Cn1cnc2c(C#N)nc(-c3ccc(OCCC4CCN(Cc5ncco5)CC4)c(C(F)(F)F)c3)cc21	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(-c2ccccn2)c1)NC(=O)c1ccccc1	IC50	'='	6309.57	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(-c2nnco2)c1)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)C(=O)Nc1ccn[nH]1	IC50	'='	20000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CCCC[C@H](NC(=O)O[C@H](Cn1cnc(-c2ccc(C(F)(F)F)cc2)c1)C(C)(C)C)C(=O)C(=O)Nc1nccs1	IC50	'='	870000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(-c2nnc(CN)o2)c1)C(=O)NCC#N	IC50	'='	3981.07	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(F)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC(C#N)(C1CC1)C1CC1	IC50	'='	100.0	nM	Inhibition of cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC(C#N)(C1CCC1)C1CCC1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CC(C)CC(C(=O)NCC#N)c1cccc(-c2cccnc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
Cc1ccc(S(=O)(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)N[C@@H](CO)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C)cc1	IC50	'>'	150000.0	nM	Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	54000.0	nM	Inhibition of cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCc1ccccc1	IC50				Inhibition of cathepsin B
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C3CCNCC3)cc2)c1	IC50	'='	1075.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
NC(=S)N/N=C(/c1cccc(Br)c1)c1cccnc1Br	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
N#CCNC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)C[C@H]1C(=O)N1CCOCC1	IC50	'='	6200.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	1.8	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CCCC[C@@H](C=O)NC(=O)O[C@@H](CC)Cc1ccccc1	IC50	'='	72.0	nM	Inhibitory concentration against recombinant human cathepsin B was determined in a fluorescence assay using 10 uM Cbz-Phe-Arg-AMC as substrate
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccc(F)cc2)o1)C(C)(C)C)C(=O)C(=O)Nc1cc[nH]n1	IC50	'='	3500000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CCCC[C@H](NC(=O)OCC1(Cc2ccccc2)CCCC1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	5000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
CN(C)C1CCN(c2ccc(Nc3ncc(Cl)c(Nc4cccc(C(F)(F)F)c4)n3)nc2)CC1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate pretreated for 60 mins followed by substrate addition incubated for 30 mins
N#C[C@H](COCc1cccc(C(=O)O)c1)NC(=O)[C@H](Cc1ccccc1)Nc1ccccc1	IC50	'='	832.0	nM	Inhibitory activity against cathepsin B (catB)
Cc1ccc2c(c1)/C(=N/NC(N)=S)CCS2	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CS(=O)(=O)N[C@H](COCc1ccccc1)C(=O)N[C@H](C=O)Cc1ccccc1	IC50	'='	42.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
N#CN1CCCC1CNC(=O)c1ccccc1	IC50	'='	75000.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O	IC50	'>'	1000000.0	nM	Compound was tested for inhibition of human liver Cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cn1cc(-c2ccc(C(F)(F)F)cc2)cn1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	72.0	nM	Inhibition of human recombinant cathepsin B
N#Cc1nc(NCc2ccc(Br)cc2)c2ncn(Cc3ccccc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCOC(=O)/C=C/C(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	140.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CC(C)CC(NC(=O)c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(=O)N(C)N(C)C#N	IC50	'='	915.0	nM	Inhibition of human liver cathepsin B
N#CN1CCC1	IC50	'='	2000.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
CCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)NCc1ccccc1	IC50	'>'	1000000.0	nM	Compound was tested for inhibition of human liver Cathepsin B
CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(F)(F)C(F)(F)F	IC50	'='	416000.0	nM	Compound was tested for inhibition of human liver Cathepsin B
Cc1cc(CN)cc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	358.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
Cc1ccc(/C(=N\NC(N)=S)c2cc(Cl)cc(Cl)c2)cc1	IC50	'='	1800.0	nM	Inhibition of human cathepsin B
Cc1ccc(/C(=N/NC(N)=S)c2cccc(C(F)(F)F)c2)cc1	IC50	'='	210.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](NC(=O)c2ccc(F)cc2F)C(=O)N[C@H](C#N)CCCc2cccc(C(=O)O)c2)c1	IC50	'='	110.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
NC(=S)N/N=C(/c1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cccs1	IC50	'='	300.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)OCC1(Cc2ccc(F)cc2)CCC1)C(=O)C(=O)Nc1ccn[nH]1	IC50	'>'	500.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
COc1ccc(/C=C/C(=O)NC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1OC	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
COc1ccc(/C=C/C(=O)NC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)cc1OC	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CC(C)C(NC(=O)OCc1ccccc1)C(=O)N1CCCCN1C#N	IC50	'='	11.0	nM	Inhibition of human recombinant cathepsin B
Cc1cccc(NC(C(=O)N2CCCCN2C#N)C(C)C)c1	IC50	'='	32.0	nM	Inhibition of human recombinant cathepsin B
CC(C)C(Nc1ccc(Cl)cc1)C(=O)N1CCCCN1C#N	IC50	'='	110.0	nM	Inhibition of human recombinant cathepsin B
NC(=S)N/N=C1\CCNc2c(Cc3ccccc3)cccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCCSc2cc(F)c(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCCSc2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCCCc2ccccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
Cc1nnc(-c2cccc(C[C@H](NC(=O)c3cc(C(C)(C)C)nn3C)C(=O)NCC#N)c2)o1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
NC(=S)N/N=C(/c1cccc(Br)c1)c1ccccc1Cl	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1cccc(C(F)(F)F)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(\c1ccc(Cl)cc1)c1ccc(Br)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#CSCC(=O)N1c2ccccc2Sc2ccc(C#N)cc21	IC50	'>'	50000.0	nM	Inhibition of Cathepsin B (unknown origin) using Z-RR-AMC as fluorogenic substrate preincubated for 10 mins followed by substrate addition and measured for 10 mins by fluorescence based assay
N#Cc1nn(-c2cccc(C(F)(F)F)c2)c(=O)n(CCCN2CCCCC2)c1=O	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
N#CC1(NC(=O)[C@H](CCCCN)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'='	1270.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](NC(=O)c2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	9.4	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC[C@@H](C)[C@H](NC(=O)NCc1ccccc1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	270.0	nM	Inhibition of human cathepsin B
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1cccc(O)c1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	150.0	nM	Inhibition of cathepsin D
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(Br)cc2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	3453.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)CCCc2cccc(C(=O)O)c2)c1	IC50	'='	18.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CCCCn1cnc2c(NCc3ccc(Br)cc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCCc2ccccc2)c2ncn(Cc3cccnc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCO[C@H]12)OCc1ccccc1	IC50	'='	1760.0	nM	In vitro Inhibitory activity against Cathepsin B cysteine protease by using Cbz-Phe-Arg-AMC
Cc1noc(-c2ccc([C@H](N[C@@H](CC(C)C)C(=O)NCC#N)C(F)(F)F)cc2)n1	IC50	'='	4073.0	nM	Inhibition of Cathepsin B
CC[C@@H](C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	1500.0	nM	Inhibition of human cathepsin B
CCCCn1cnc2c(NCc3ccc(Cl)c(Cl)c3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCn1cnc2c(NCc3ccc(Cl)cc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
COc1ccc(/C(=N/NC(N)=S)c2cccc(/C(=N/NC(N)=S)c3ccc(OC)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
CN(/N=C(/c1ccccc1)c1cccc(C(=O)c2ccccc2)c1)C(N)=S	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
N#Cc1nc(Nc2cccc([N+](=O)[O-])c2)nc(N2CCNCC2)n1	IC50	'='	34.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CCCCS(=O)(=O)C[C@@H](NC(=O)c1cnccc1O)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	770.0	nM	Inhibition of cathepsin D
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)OC)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	126.0	nM	Inhibition of cathepsin D
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2nc3ccccc3s2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	2971.0	nM	Inhibition of human cathepsin B
N#Cc1nc(CCCN2CCCCC2)cc(C2CCCCCC2)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B by fluorescence assay
N#Cc1nc(NCc2cccc(-c3ccccc3Cl)c2)c2ncn(CCCO)c2n1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
Cc1ccccc1-c1cccc(CNc2nc(C#N)nc3c2ncn3CCCO)c1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2cccc(-c3ccoc3)c2)c2ncn(CCCO)c2n1	IC50	'='	8600.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2cccc(-c3ccc(Cl)cc3)c2)c2ncn(CCCO)c2n1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
N#CN1CCCC1	IC50	'='	15000.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
C[C@@H](NC(=O)N1C(=O)CC1SCc1ccccn1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2nccs2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	4818.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2cccc(F)c2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	2476.0	nM	Inhibition of Cathepsin B
CN1CCN(c2ccc(-c3cccc(CC(=O)NCC#N)c3)cc2)CC1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
N#CCNC(=O)[C@H](Cc1ccc(I)cc1)NC(=O)C(c1ccccc1)c1ccccc1	IC50	'>'	1000.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
C[C@@H](OCc1ccccc1)[C@@H](C#N)NC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1ccc(-c2ccccc2)cc1	IC50	'='	57.8	nM	Inhibition of human cathepsin B at pH 6 using Z-Phe-Arg-AMC fluorogenic peptide as substrate preincubated for 2 mins followed by substrate addition and measured for 5 mins by fluorescence assay
C[C@@H](OCc1ccccc1)[C@@H](C#N)NC(=O)[C@H](Cc1cccc(Br)c1)NC(=O)c1ccc(-c2ccccc2)cc1	IC50	'='	39.4	nM	Inhibition of human cathepsin B at pH 4.5 using Z-Phe-Arg-AMC fluorogenic peptide as substrate preincubated for 2 mins followed by substrate addition and measured for 5 mins by fluorescence assay
CC(C)C[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	518.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(OCC(F)(F)F)cc2C(F)(F)F)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	291.1	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#C[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1S(=O)(=O)c1ccc(-c2ccccc2)cc1	IC50	'>'	50000.0	nM	Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC fluorogenic substrate
NC(=S)N/N=C(\c1cc(O)cc(O)c1)c1cc(Br)cc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin-B using Z-RR-AMC as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by fluorometric method
N#CN1CCC(CCc2ccccc2)C1	IC50	'='	5011.87	nM	Inhibition of human recombinant cathepsin B after 1 hr
C#C[C@H](COCc1cccc(C(=O)O)c1)NC(=O)[C@H](Cc1cccc(C)c1)NC(=O)c1ccc(F)cc1	IC50	'='	15800.0	nM	Inhibition of cathepsin B in live human U-251MG cells using e Abz-GIVRAK(Dnp)-NH2 as substrate preincubated for 30 mins followed by substrate addition by fluorescence based analysis
C/N=c1\nc(-c2ccc(F)cc2)n(-c2ccccc2)s1	IC50	'>'	50000.0	nM	Inhibition of human Cathepsin B using Z-RR-AMC as substrate preincubated for 30 mins followed by substrate addition measured for 10 mins by FRET assay
N#Cc1ccc(Nc2nc(C#N)nc(NC3CCCCC3)n2)cc1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CC(C)C[C@@H](COC1CC(=O)N1C(=O)N[C@H](C)c1ccccc1)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
COc1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)cc1OC	IC50	'='	3060.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#Cc1nc(Nc2cc(F)cc(F)c2)nc(NC2CCCC2)n1	IC50	'='	10000.0	nM	Inhibition of human Cathepsin B
CCn1cnc2c(Nc3cc(F)cc(F)c3)nc(C#N)nc21	IC50	'='	10715.19	nM	Inhibition of human Cathepsin B
Cc1ccccc1/C(=N\NC(N)=S)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
Cc1cccc(/C(=N\NC(N)=S)c2cccc(Br)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(/c1ccc(Br)cc1)c1ccccc1Br	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
Cc1cccc(C[C@H](Nc2ccc3c(c2)C(=O)CC3)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	5.3	nM	Inhibitory activity against cathepsin B (catB)
Cc1cccc(C[C@H](NC(=O)c2ccc(Cl)cc2F)C(=O)NCC#N)c1	IC50	'='	72.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CCCC[C@H](NC(=O)OC(Cc1nnc(-c2ccc(F)cc2)o1)C(C)(C)C)C(=O)C(=O)N[C@H]1CCCNC1=O	IC50	'='	6200.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
C[C@H](NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)C(F)(F)F	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CCC[C@H](NC(=O)[C@@H]1C[C@@H](OCc2ccc3ccccc3c2)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)C1CCCCC1)C(C)C)C(=O)O	IC50	'>'	300000.0	nM	Compound was evaluated for its inhibitory activity against cathepsin B
CNC(=O)C(=O)C(C)NC(=O)c1ccc(OCc2ccccn2)c(C(F)(F)F)c1Cl	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B by fluorescence assay
N#CN1CCC(CNS(=O)(=O)c2ccccc2)C1	IC50	'='	1500.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
N#CN1CCC(NC(=O)c2ccccc2)C1	IC50	'='	4200.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
CCCc1cc(-c2cccc(C)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cccc(-c2cc(CCC)nc(C#N)n2)c1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2ccc(C)c(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCCS(=O)(=O)C[C@@H](NC(=O)SC1CCOC1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	436.0	nM	Inhibition of cathepsin D
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1ccc(C(F)(F)F)cc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	316.0	nM	Inhibition of cathepsin D
COc1ccc2c(O[C@@H]3C[C@H](C(=O)N[C@@H](CC4CC4)C(=O)C(=O)NC4CC4)N(C[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)C3)nccc2c1	IC50	'='	27.0	nM	Inhibition of human liver cathepsin B using Boc-Leu-Arg-Arg-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by spectrofluorimetric analysis
NC(=S)N/N=C(/c1cccc(Br)c1)c1ccccc1Br	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
Cc1nc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)c(C)o1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CCCc1cc(-c2cccc(Cl)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(C(=N)N)c1)NC(=O)C(c1ccccc1)c1ccccc1	IC50	'>'	1000.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CN1CCN(c2ccc(-c3cccc(C(CC4CCC4)C(=O)NCC#N)c3)cc2)CC1	IC50	'='	8055.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
N#Cc1nc(NCc2cccc(-c3ccc(Cl)c(Cl)c3)c2)c2ncn(CCCO)c2n1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
S=C(NN=C(c1cccc(Br)c1)c1cccc(Br)c1)Nc1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NC[C@H](O)c2ccccc2)nc(N2CCNCC2)n1	IC50	'='	136.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
COc1ccc(Nc2nc(C#N)nc(NC3CCCCC3)n2)cc1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
Cn1cc(-c2cccc(C[C@H](NC(=O)c3ccccc3)C(=O)NCC#N)c2)cn1	IC50	'='	6309.57	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N	IC50	'='	6309.57	nM	Inhibition of cathepsin B
CCC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)NCC=O	IC50	'='	3200.0	nM	Inhibition of human cathepsin B
CC[C@@H](C)[C@H](NC(=O)Nc1cccc2ccccc12)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	370.0	nM	Inhibition of human cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCc1ccccc1	IC50	'='	20000.0	nM	Inhibition of cathepsin B
Cc1ccc(S(=O)(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C)cc1	IC50				Inhibition of cathepsin B
CN(C)CCCOc1ccc(-c2cc3c(ncn3C)c(C#N)n2)cc1C(F)(F)F	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
O=C1NN(c2ccc(Cl)c(C(=O)O)c2)C(=O)/C1=C\c1ccc(-c2ccc(Cl)cc2)o1	IC50	'='	88900.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cn1cnc2cc(Cl)c(Cl)cc21)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	40.0	nM	Inhibition of human recombinant cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)CF)OCc1ccccc1	IC50	'='	65.6	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2nccs2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	3612.0	nM	Inhibition of human cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1cccc(F)c1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	3854.0	nM	Inhibition of human cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)C1=CCCCC1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CSc1cc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3CCCCN3)cc2)ccc1C#N	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin)
CCN(CC)C(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCOCC3)cc2)c1	IC50	'='	1744.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C(N)=O)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCCS(=O)(=O)C[C@@H](NC(=O)c1ccncc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	1260.0	nM	Inhibition of cathepsin D
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)OCc1ccncc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	158.0	nM	Inhibition of cathepsin D
CC(C)C[C@H](CC[S+]([O-])c1ccc2ccccc2c1)C(=O)N[C@H](C=O)CC(C)C	IC50	'='	60.0	nM	Inhibitory activity using cysteine protease, Cathepsin B with Cbz-Phe-Arg-AMC as substrate.
N#CC1(NC(=O)[C@H](Cc2ccc(O[C@@H]3CCNC3)cc2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'='	2241.0	nM	Inhibition of human cathepsin B
CC[C@H](C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(C)CC3)cc2)c1	IC50	'='	5788.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(CC(C)(C)O)CC3)cc2)c1	IC50	'='	6369.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)[C@@H](C)CC	IC50	'='	2.28	nM	Inhibition of cathepsin B (unknown origin) assessed as reduction in 7-amino-4-methylcoumarin formation using Z-Arg-Arg-MCA as substrate preincubated for 3 mins followed by substrate addition and measured after 10 mins by fluorescence spectrometric method
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C3COCCN3)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCCC(=O)N[C@@H](Cc1cccc(C)c1)C(=O)N[C@H](C#N)COCc1cccc(C(=O)O)c1	IC50	'<'	10.0	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCc1cccc2ccccc12	IC50	'='	385.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N1Cc2ccccc2C1=O)C(C)(C)C)C(=O)C(=O)NCc1ccc(S(N)(=O)=O)cc1	IC50	'='	3049.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
NC1=N[C@@]2(CS1)c1cc(-c3cccnc3F)ccc1O[C@@H]1CCCO[C@H]12	IC50	'>'	200000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
COc1cccc(Nc2nc(C#N)nc(NC3CCNCC3)n2)c1	IC50	'='	10000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
N#Cc1nc(Nc2cccc(OC(F)(F)F)c2)nc(N2CCOCC2)n1	IC50	'='	74000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CC(C)CC(C(=O)NCC#N)c1cncc(-c2ccccc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CN(C)C(=O)C[C@H](NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)N[C@H]1CN(OCc2ccccc2)C1=O	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(-n3cnnn3)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCC[C@@H](C=O)NC(=O)OC(CC)(CC)Cc1ccccc1	IC50	'='	2200.0	nM	Inhibitory concentration against recombinant human cathepsin B was determined in a fluorescence assay using 10 uM Cbz-Phe-Arg-AMC as substrate
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(=O)NC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'>'	150000.0	nM	Inhibition of cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccncc2)n1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	13.0	nM	Inhibition of human recombinant cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cn1cnc(-c2ccc(C(F)(F)F)cc2)c1)C(C)(C)C)C(=O)CNS(=O)(=O)c1ccccn1	IC50	'='	130.0	nM	Inhibition of human recombinant cathepsin B
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc(C(F)(F)F)c(Cl)s3)CC2)CC1	IC50	'='	5011.87	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
Cn1cc(-c2cccc(C[C@H](NC(=O)c3cc(C(C)(C)C)nn3C)C(=O)NCC#N)c2)cn1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
N#CCNC(=O)[C@H](Cc1cccc(-c2ccn[nH]2)c1)NC(=O)c1ccccc1	IC50	'='	5011.87	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC(N)=O	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CSCC[C@H](NC(=O)[C@H](CC(C)C)N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(N)=O	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CCCC[C@@H](C#N)n1cc([C@@](C)(NC(=O)c2ccccc2)C(C)C)nn1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CCCC[C@H](NC(=O)OC1C2CC3CC(C2)CC1C3)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	5000.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
O=C(/C=C/c1ccc(O)c2ccccc12)c1ccc(O)cc1O	IC50	'='	6340.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
CCNC(=O)C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)[C@@H](NC(=O)CCCCC1CCSS1)C(C)C	IC50	'='	40.0	nM	Inhibitory activity against cathepsin B
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(C)CC3)cc2)c1	IC50	'='	3843.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)c1ccccc1)C(=O)C(=O)NCc1ccccc1	IC50	'='	446.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCCCC2)CC1	IC50	'='	3600.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CCOCC2)CC1	IC50	'='	8500.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CC(C)(C#N)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)C[C@H]1C(=O)N1CCOCC1	IC50	'>'	25000.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CCC(NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(=O)c1ccc(-c2ccccc2)cc1)C(=O)c1nc2ccccc2o1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin-B
COc1ccc(C(=O)NCC(=O)NCC#N)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1	IC50	'>'	100000.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NCc1ccc(CN(C)C)cc1	IC50	'='	242.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
Cc1nc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)sc1C	IC50	'='	2511.89	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4c(s3)CCC4)CC2)CC1	IC50	'='	1995.26	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)COCc2ccc(C(=O)O)cc2)c1	IC50	'='	30.7	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	5.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CCc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	136.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
C[C@]12CCCO[C@@H]1[C@]1(CSC(N)=N1)c1cc(-c3cncnc3)ccc1O2	IC50	'='	64000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CCCCS(=O)(=O)C[C@@H](NC(=O)c1cnccn1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	133.0	nM	Inhibition of cathepsin D
CC(C)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	2993.0	nM	Inhibition of Cathepsin B
CCOC(=O)/C=C/C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)N1CCOCC1	IC50	'='	90.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
COc1ccc(C(=O)/C=C/c2ccc(F)cc2)c(O)c1	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
O=C(/C=C/c1ccc(F)cc1)c1ccc(O)cc1	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
COc1ccc(/C=C/C(=O)c2ccco2)cc1Br	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
CCCC[C@@H](C=O)NC(=O)OC(C)(C)C	IC50	'='	32000.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
CCCC[C@@H](C=O)NC(=O)O[C@H](Cc1ccccc1)C(C)C	IC50	'='	27.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
N#CCNC(=O)[C@H](Cc1cccc(-c2cn[nH]c2)c1)NC(=O)c1ccccc1	IC50	'='	7943.28	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCS[C@@H]12)OCc1ccccc1	IC50	'>'	50000.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
CC(NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)C(F)(F)C(F)(F)F	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccccc2)o1)C(C)(C)CC)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	56000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccc(C(F)(F)F)cc2)o1)C(C)(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	32000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
N#Cc1nc(Nc2ccc(F)cc2)nc(N2CCOCC2)n1	IC50	'='	160000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
O=C(CF)CNC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1	IC50	'='	700.0	nM	Inhibition of recombinant human cathepsin B (332 residues) expressed in CHO cells using Z-FR-AMC as substrate preincubated for 20 mins followed by substrate addition by fluorescence plate reader analysis
CCCC[C@H](NC(=O)O[C@H]1CCc2ccccc21)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	13000.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(=O)OC1CCCCC1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
CCc1nnc(NS(=O)(=O)c2ccc(NC(=O)Nc3ccc(Cl)cc3)cc2)s1	IC50	'='	5200.0	nM	Inhibition of human cathepsin B
Cc1cccc(O[C@@H]2CCNC[C@@H]2O)c1C	IC50	'>'	100000.0	nM	Inhibition of human recombinant cathepsin B
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2C(F)(F)F)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	245.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)(C#N)c1cnc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)s1	IC50	'='	5011.87	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4cccnc4s3)CC2)CC1	IC50	'='	25118.86	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(C)cc2C)CN1C(=O)OC(C)(C)C)C(=O)C(=O)NC1CC1	IC50	'='	11069.5	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(F)c(F)c2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	8869.0	nM	Inhibition of Cathepsin B
CCOC(=O)/C=C/C(=O)[C@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	70.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCc1ccccc1	IC50	'='	77.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#CCNC(=O)C1(NC(c2ccc(-c3ccc(N4CCNCC4)cc3)cc2)C(F)(F)F)CCCCC1	IC50	'>'	10000.0	nM	Inhibitory activity against cathepsin B from human
C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCCC2)ccc1C	IC50	'='	3000.0	nM	Inhibition of recombinant human C-terminal polyhistidine-tagged cathepsin B (Arg18 to Ile339 residues) expressed in HEK293 cells using Z-Leu-Arg-AMC as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins
O=C(/C=C/c1ccc(O)c2ccccc12)c1cccs1	IC50	'>'	50000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
O=C(/C=C/c1ccc(O)c2ccccc12)c1ccc(O)cc1	IC50	'='	14810.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
N#Cc1nc(Nc2ccc(F)cc2)nc(NC2CCNCC2)n1	IC50	'='	4300.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
C[C@@H]1C[C@@H](NS(=O)(=O)c2cccc(Br)c2)CN1C#N	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
C[C@H]1C[C@@H](NS(=O)(=O)c2cc(Br)ccc2Br)CN1C#N	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
Cn1cnc2c(C#N)nc(-c3ccc(OCCC4CCNCC4)c(C(F)(F)F)c3)cc21	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(-c2ccncc2)c1)NC(=O)c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
Cc1cccc(O[C@H]2CCN3C[C@@H]2OC3=O)c1C	IC50	'='	46.0	nM	Inhibition of human recombinant cathepsin B
CC(C)(c1ccc(F)cc1)S(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)CC2CC2)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	1000.0	nM	Inhibition of human cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccccc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	1980.0	nM	Inhibition of human cathepsin B
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	1800.0	nM	Inhibition of human liver cathepsin B pre-incubated for 17 hrs in non-buffer solution without DTT
CC(C)CS(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	337.0	nM	Inhibition of human cathepsin B
COc1cc(O)ccc1/C=C/C(=O)c1ccc(N)cc1	IC50	'='	76470.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
NC(=S)N/N=C(\c1ccc(F)cc1)c1cccc(C(=O)c2ccc(F)cc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	97.3	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC(C)C	IC50	'='	187.1	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
Cc1nn(C)c2ccc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)[C@H](C)C3)cc12	IC50	'='	971.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
CC1CN(c2ccc(S(C)(=O)=O)cc2)C(C)CN1C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	40000.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
NC(=S)N/N=C(/CCc1ccccc1)c1cccc(F)c1	IC50	'='	22000.0	nM	Inhibition of human cathepsin B
N#Cc1nc(NCc2cccc(-c3cccnc3)c2)c2ncn(CCCO)c2n1	IC50	'='	3900.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2cccc(-c3c(F)c(F)c(F)c(F)c3F)c2)c2ncn(CCCO)c2n1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
CN(C)c1cccc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)c1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(Cl)c(Cl)c2)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	4813.0	nM	Inhibition of human cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(-c2ccc(F)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	170.0	nM	Inhibition of human cathepsin B
CC(C)C[C@H](NC(=O)c1ccc(-c2ccccc2)cc1)C(=O)NC1(C#N)CCS(=O)(=O)CC1	IC50	'='	2500.0	nM	Inhibition of human cathepsin B
N#CCNC(=O)C1(NC(=O)c2ccc(N3CCOCC3)cc2)CCCCC1	IC50	'='	15400.0	nM	Inhibitory activity against human cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)C(c1ccccc1)c1ccccc1	IC50				Inhibition of cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N[C@H](C(=O)OC(C)(C)C)C(C)(C)C)NC(=O)OCc1ccccc1	IC50				Inhibition of cathepsin B
CCCCOc1ccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2ccccc2)C(=O)O)cc1	IC50	'='	836.0	nM	Compound was tested for its inhibitory activity against cathepsin B
CS(=O)(=O)c1ccc(-c2ccc([C@H](N[C@@H](CC(Cl)Cl)C(=O)NC(C#N)(C3CC3)C3CC3)C(F)(F)F)cc2)cc1	IC50	'='	1528.0	nM	Inhibition of cathepsin B
Cc1ccc(S(=O)(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C)cc1	IC50	'='	13000.0	nM	Inhibition of cathepsin B
CCCC[C@H](N[C@@H](CC(C)C)C(=O)NCC#N)C(F)(F)F	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2cc(F)cc(F)c2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(C#N)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	7392.0	nM	Inhibition of Cathepsin B
COc1ccc(-c2ccc([C@H](N[C@@H](CC(C)C)C(=O)NCC#N)C(F)(F)F)cc2)cc1	IC50	'='	1660.0	nM	Inhibition of Cathepsin B
Cc1ccc(-c2ccc([C@H](N[C@@H](CC(C)C)C(=O)NCC#N)C(F)(F)F)cc2)cc1	IC50	'='	1337.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(F)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	5939.0	nM	Inhibition of Cathepsin B
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(=O)C(C)C)n3)nc3c(Br)c(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC1CCCC1)C(C)(C)C)C(=O)O	IC50	'='	26000.0	nM	Inhibition of human CatB after 60 mins fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NC1CCN(C)CC1	IC50				Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)N[C@@H](C)c1ccccc1	IC50				Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CNC(=O)c1ccc(CNC(=O)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](N2Cc3ccccc3C2=O)C(C)(C)C)C(C)C)cc1	IC50	'='	3571.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(=O)c1c(Nc2ccc(Cl)cc2Cl)[nH]c2c(Cl)ccc(Cl)c2c1=O	IC50	'='	3890.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	77000.0	nM	Inhibition of cathepsin B
Cc1ccc(S(=O)(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)NC(C)(C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C)cc1	IC50				Inhibition of cathepsin B
CN(C)S(=O)(=O)NCCCC[C@H](NC(=O)OCC1(Cc2ccc(F)cc2)CCC1)C(=O)C(=O)NCc1cccnc1	IC50	'>'	5000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
CCCC[C@H](NC(=O)OCC1(Cc2ccccc2)CCC1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	3600.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
CC(C)(C)CNc1nc(C#N)nc(N2CCOCC2)c1N	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
N#Cc1nc(Nc2cccc([N+](=O)[O-])c2)nc(NC2CCCCC2)n1	IC50	'='	79.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
N#CC1(NC(=O)[C@H](Cc2cccnc2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'='	2751.0	nM	Inhibition of human cathepsin B
CCN(CC)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CCN(CC)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@@H]1CCCN1C(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CC1=NN(c2ccc(Cl)c(C(=O)O)c2)C(=O)/C1=C\c1ccc(C(C)C)cc1	IC50	'='	22400.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)OCC1(CCc2ccccc2)CCC1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	2000.0	nM	Inhibition of 10 uM Cbz-Phe-Arg-AMC binding to human cathepsin B in fluorescence assay
NC(=S)N/N=C(/c1ccccc1)c1cccs1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1ccccc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	495.0	nM	Inhibition of cathepsin D
CCCCS(=O)(=O)C[C@@H](NC(C)=O)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	360.0	nM	Inhibition of cathepsin D
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(C)=O)C(=O)c1nc2ccccc2o1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin-B
NC(=S)N/N=C1\CCSc2c(F)cc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCSc2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
C[C@]12CCCO[C@@H]1[C@]1(CSC(N)=N1)c1cc(-c3cccnc3F)ccc1O2	IC50	'='	24000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CN(C)c1ccc(C[C@H](NC(=O)c2ccc(-c3ccccc3)cc2)C(=O)NC2(C#N)CC2)cc1	IC50	'='	715.0	nM	Inhibition of human cathepsin B
CC(C)CN(NC(=O)c1ccc(CN2CCN(C)CC2)cc1)c1nc(C#N)ncc1Br	IC50	'='	987.0	nM	Inhibition of human cathepsin B
CC[C@@H](C)[C@H](NS(=O)(=O)c1ccc2ccccc2c1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	23.0	nM	Inhibition of human cathepsin B
C[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	530.0	nM	Inhibition of human cathepsin B
CC(C)Oc1ccc(C(=O)c2cccc(/C(=N/NC(N)=S)c3ccc(OC(C)C)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccc(C(F)(F)F)cc2)o1)C(C)(C)C)C(=O)C(=O)NN1CCOC1=O	IC50	'='	5200.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CN1CCN(C(=O)C[C@H](NC(=O)c2ccc(-c3ccccc3)cc2)C(=O)NC2(C#N)CC2)CC1	IC50	'>'	5000.0	nM	Inhibition of human cathepsin B
CC(C)C[C@H](NC(=O)c1ccc(CN2CCN(C)CC2)cc1)C(=O)NC1(C#N)CCS(=O)(=O)CC1	IC50	'='	2320.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1cc(O)cc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CCCCS(=O)(=O)C[C@@H](NC(=O)COC)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	1535.0	nM	Inhibition of cathepsin D
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1ccccc1C)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	404.0	nM	Inhibition of cathepsin D
NC(=S)N/N=C1\CCS(=O)(=O)c2ccc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
N=C1S/C(=C\c2ccc(-c3ccc(O)c(C(=O)O)c3)o2)C(=O)N1c1nccs1	IC50	'='	72300.0	nM	Inhibition of human cathepsin B
CC(C)C[C@@H](/C=C/S(C)(=O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)NC(C)(C)C(=O)OC(C)(C)C)NC(=O)OCc1ccccc1	IC50				Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	27000.0	nM	Inhibition of cathepsin B
CC(=O)N[C@@H](CCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	850.0	nM	Inhibition of cathepsin B
CC(=O)N[C@@H](CCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	1600.0	nM	Inhibition of cathepsin B
CC(=O)N[C@@H](CCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'>'	150000.0	nM	Inhibition of cathepsin B
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
N#Cc1nc(Nc2ccc(OC(F)(F)F)cc2)nc(NC2CCNCC2)n1	IC50	'='	800.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CC(C)C[C@H](Nc1cscc1Br)C(=O)NCC#N	IC50	'='	158.0	nM	Inhibitory concentration against human cathepsin B
CCOC(=O)c1cc([Se]c2ccccc2)c2cc(C)ccc2n1	IC50				Inhibition of cathepsin B (unknown origin) using Z-FR-AMC as substrate by spectrofluorometric analysis
N#CC1(NC(=O)[C@H](Cc2ccncc2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'>'	5000.0	nM	Inhibition of human cathepsin B
O=C(N[C@@H](Cc1cccnc1)C(=O)N[C@@H]1C(=O)N2CCS(=O)(=O)[C@@H]12)OCc1ccccc1	IC50	'='	1300.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
S=C1O[C@@H]2CN1CC[C@@H]2Oc1ccccc1	IC50	'='	519.0	nM	Inhibition of human recombinant cathepsin B
CC(=O)c1c(Nc2ccc(Cl)cc2Cl)[nH]c2c([N+](=O)[O-])cc(Cl)cc2c1=O	IC50	'='	12690.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CCCCn1cnc2c(NC(C)c3ccccc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(F)cc2)c2ncn(Cc3ccccc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccccc2)c2ncn(CCCO)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCCc2ccccc2)c2ncn(Cc3ccccc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(Cc3ccccc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	1700.0	nM	Inhibition of human liver cathepsin B pre-incubated for 2 hrs in non-buffer solution without DTT
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	700.0	nM	Inhibition of human liver cathepsin B pre-incubated for 17 hrs in buffer without DTT
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccc(F)cc2)o1)C(C)(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	9800.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
NC(=S)N/N=C1\CCSc2ccc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CCCC[C@H](NC(=O)O[C@H](Cn1ccc(-c2ccc(C(F)(F)F)cc2)n1)C(C)(C)C)C(=O)C(=O)NCc1ccno1	IC50	'='	870000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
COC(=O)c1ccc(-c2cccc(CNc3nc(C#N)nc4c3ncn4CCCO)c2)cc1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C1\CCN([N+](=O)[O-])c2ccccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	5800.0	nM	Inhibition of cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(N)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	1561.0	nM	Inhibition of Cathepsin B
CC(=O)N[C@@H](CC(=O)NCCCCOCc1ccccc1)C(=O)N[C@@H](CC(C)C)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1	IC50	'>'	30000.0	nM	Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate by spectrofluorometer analysis
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4ccc(C(F)(F)F)cc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4ccccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CCCC[C@H](NC(=O)O[C@@H]1C(=O)NCC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	1400.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
CCCC[C@H](NC(=O)OC1CC2CCC1C2)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	13000.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NCC(=O)N1CCOCC1	IC50	'='	88.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
COc1ccc(/C=C/C(=O)/C=C/c2ccc(O)cc2OC)cc1	IC50	'='	37760.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
NC(=S)N/N=C1\CCS(=O)(=O)c2ccc(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)C1CC[N+](C)(C)CC1)C(C)(C)C)C(=O)C(=O)NCc1ccccc1.O=C[O-]	IC50	'='	274.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
Cc1n[nH]c(C)c1C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NC(C(=O)C(=O)NCc1ccccc1)C(C)C)C(C)(C)C	IC50				Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
COc1cccc(/C=C/C(=O)NC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)c1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
Cc1ccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)cc1C	IC50	'='	11.9	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
CC(=O)N1CC/C(=N\NC(N)=S)c2ccccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CCOc1cc(O)ccc1C(=O)/C=C/C=C/c1ccccc1OC	IC50	'='	13870.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
COc1cc(O)ccc1C(=O)/C=C/c1ccc(O)c2ccccc12	IC50	'='	15650.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
	IC50	'='	150000.0	nM	Inhibitory concentration against human liver cathepsin B
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NCC(=O)N1CC[N+](C)(C)CC1.O=C[O-]	IC50	'>'	2500.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
N=C(N)N/N=C1\CCSc2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)c1cccnc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	186.0	nM	Inhibition of cathepsin D
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](COCc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	38000.0	nM	Inhibition of cathepsin B
CCCC[C@H](NC(=O)O[C@@H]1C[C@H](C)C[C@H](C)C1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	13000.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCNC(=N)N	IC50	'='	9.4	nM	Inhibition of human cathepsin B
CC[C@@H](C)[C@H](/N=C(\S)NCc1ccccc1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	410.0	nM	Inhibition of human cathepsin B
COc1ccc(/C=C/C(=O)c2ccc(F)cc2)cc1Br	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
N#CN1CC[C@@H](NS(=O)(=O)c2ccccc2)C1	IC50	'='	10000.0	nM	Inhibition of human recombinant cathepsin B after 1 hr
Cn1cnc2c(C#N)nc(-c3ccc(OCCC4CCN(S(C)(=O)=O)CC4)c(C(F)(F)F)c3)cc21	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
CC(C)C[C@@H](O)C(=O)N1CC2(CC2)C[C@H]1C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COC(F)(F)F	IC50	'='	4300.0	nM	Inhibition of human Cathepsin B
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccccn2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCC[C@@H](C#N)n1cc([C@@](C)(NC(=O)c2ccsc2)C(C)C)nn1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CC(C)C[C@@H](CCS(=O)(=O)c1ccc2ccccc2c1)C(=O)N[C@H](C=O)CC(C)C	IC50	'='	4500.0	nM	Inhibitory activity using cysteine protease, Cathepsin B with Cbz-Phe-Arg-AMC as substrate.
CC(C)C[C@H](CCS(=O)(=O)c1ccc2ccccc2c1)C(=O)N[C@H](C=O)CC(C)C	IC50	'='	150.0	nM	Inhibitory activity using cysteine protease, Cathepsin B with Cbz-Phe-Arg-AMC as substrate.
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)C(c1ccccc1)c1ccccc1	IC50	'='	130.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC(C)CC(C(=O)NCC#N)c1csc(-c2ccccc2)n1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
C[C@@H](OCc1ccccc1)[C@@H](C#N)NC(=O)[C@H](Cc1cccc(Br)c1)NC(=O)c1ccc(-c2ccccc2)cc1	IC50	'='	92.6	nM	Inhibition of human cathepsin B at pH 6 using Z-Phe-Arg-AMC fluorogenic peptide as substrate preincubated for 2 mins followed by substrate addition and measured for 5 mins by fluorescence assay
Cc1cccc(C[C@H](Nc2ccc3c(c2)C(=O)N(C)C3)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	9.3	nM	Inhibitory activity against cathepsin B (catB)
CCCC[C@@H](C=O)NC(=O)O[C@@H](C)Cc1ccccc1	IC50	'='	460.0	nM	Inhibitory concentration against recombinant human cathepsin B was determined in a fluorescence assay using 10 uM Cbz-Phe-Arg-AMC as substrate
Cc1cccc(C[C@H](Nc2ccc3c(c2)C(=O)OC3)C(=O)N[C@H](C#N)COCc2cccc(-n3cnnn3)c2)c1	IC50	'='	5.0	nM	Inhibitory activity against cathepsin B (catB)
Cc1cccc(C[C@H](NC(=O)c2ccc(Cl)cc2)C(=O)NCC#N)c1	IC50	'='	308.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
NC(=S)N/N=C(/c1cc(Br)cc(C(=O)c2ccccc2F)c1)c1ccccc1F	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
CC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	30.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](NC(=O)c2ccc(F)cc2F)C(=O)NCC#N)c1	IC50	'='	591.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CN1CCN(c2ccc(-c3cccc(C(CC4CC4)C(=O)NCC#N)c3)cc2)CC1	IC50	'='	3433.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCc1cc(-c2cccc(OC(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2cccc(C3CCC3)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CC1=C(C#N)C(=O)NC(=O)/C1=C\c1ccc(-c2ccc(S(N)(=O)=O)cc2)o1	IC50	'='	64800.0	nM	Inhibition of human cathepsin B
C[C@@H](CC1CCCCC1)OC(=O)C1CCCN1C#N	IC50	'='	310.0	nM	Inhibitory concentration against human cathepsin B using 10 uM Cbz-Phe-Arg-AMC
C[C@@H](CC1CCCCC1)OC(=O)C1CCN1C#N	IC50	'='	2.4	nM	Inhibitory concentration against human cathepsin B using 10 uM Cbz-Phe-Arg-AMC
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCC(=O)NCC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50				Inhibition of cathepsin B
CSc1ccc2c(c1)/C(=N/NC(N)=S)CCS2	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CC(=O)Nc1ccc2c(c1)/C(=N/NC(N)=S)CCS2	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCS(=O)(=O)c2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
O=C1NC(=S)N/C1=C\c1ccc(O)cc1O	IC50	'='	52300.0	nM	Inhibition of human cathepsin B
CC(C)C[C@H](NC(c1ccc(Br)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	3353.0	nM	Inhibitory activity against cathepsin B from human
CC[C@@H](C)[C@H](/N=C(\S)Nc1cccc2ccccc12)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	310.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccccc2)o1)C(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	31000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CCN(C#N)CC	IC50	'>'	100000.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccccc2)o1)C(C)(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'='	12000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CC[C@@H](NC(=O)N1C(=O)[C@@H](C)[C@@H]1SCc1ccccn1)c1ccccc1	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
CC(=O)Nc1cccc(Nc2nc(Nc3ccc(-c4ccsc4)cn3)ncc2Cl)c1	IC50	'>'	5000.0	nM	Inhibition of human recombinant Cathepsin B using Z-Leu-Arg-AMC as substrate pretreated for 60 mins followed by substrate addition and incubated for 30 mins by microplate reader assay
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'<'	2000.0	nM	Inhibition of Cathepsin B (unknown origin) assessed as inhibition of AFC release using sequence RR labelled with AFC as substrate by fluorescence based analysis
CN1CCN(c2ccc(CN(CC(C)(C)C)c3nccc(C#N)n3)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of Cathepsin B (unknown origin) assessed as inhibition of AFC release using sequence RR labelled with AFC as substrate by fluorescence based analysis
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)C[C@@H]3CCNC3=O)cc12	IC50	'='	2000.0	nM	Inhibition of human cathepsin B
CCCC[C@H](NC(=O)O[C@H](Cn1cnc(-c2ccc(C(F)(F)F)cc2)c1)C(C)(C)C)C(=O)C(=O)Nc1ccn[nH]1	IC50	'='	27000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CC[C@@H](C)[C@H](NC(=O)Nc1ccccc1C(F)(F)F)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	220.0	nM	Inhibition of human cathepsin B
C[C@@H](OCc1ccccc1)[C@@H](C#N)NC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1cccc(-c2cccnc2)c1	IC50	'='	9.01	nM	Inhibition of human cathepsin B at pH 6 using Z-Phe-Arg-AMC fluorogenic peptide as substrate preincubated for 2 mins followed by substrate addition and measured for 5 mins by fluorescence assay
CC(C)C[C@H](Nc1cscc1-c1ccc(N2CCNCC2)cc1)C(=O)NCC#N	IC50	'='	123.0	nM	Inhibitory activity against cathepsin B from human
COc1cccc2c1CCC/C2=N\NC(N)=S	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CCCC[C@@H](C#N)n1cc([C@@](C)(NC(=O)c2ccsc2)C2CCC(C)CC2)nn1	IC50	'>'	15000.0	nM	Inhibition of cathepsin B
COc1ccc(/C=C/C(=O)c2ccc(O)cc2)cc1Br	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
CCCc1cc(-c2cccc(C3CC3)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2ccccc2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
N#CC1(NC(=O)[C@H](Cc2c[nH]c3ccc(O)cc23)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'='	1104.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)CCOc2cccc(C(=O)O)c2)c1	IC50	'='	138.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(CCO)CC3)cc2)c1	IC50	'='	3343.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCC	IC50	'='	107.6	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
O=C[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1S(=O)(=O)c1ccccc1	IC50	'='	1400.0	nM	Compound was tested for inhibitory activity against Cathepsin B.
N#CN1CC(CNC(=O)c2ccccc2)C1	IC50	'='	250.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCO[C@@H]12)OCc1ccccc1	IC50	'='	12200.0	nM	In vitro Inhibitory activity against Cathepsin B cysteine protease by using Cbz-Phe-Arg-AMC
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N2CCCS(=O)(=O)[C@H]12)OCc1ccccc1	IC50	'>'	50000.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'='	41000.0	nM	Inhibition of cathepsin B
N#CN1Cc2cc3ccccc3nc2C1	IC50	'='	2300.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
COc1ccc(/C(=N/NC(N)=S)c2cccc(/C(=N/NC(N)=S)c3ccc(O)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
O=C(/C=C/c1ccc(N2CCCC2)cc1)c1ccc(F)cc1	IC50	'='	54290.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
COc1ccc(/C=C/C(=O)c2cccs2)cc1Br	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
CC(C)C[C@@H](COC1CC(=O)N1C(=O)N[C@@H](C)c1ccccc1)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C	IC50	'>'	75000.0	nM	Inhibitory activity against Cathepsin B
O=C(O)c1cccc(N2N=C(C(F)(F)F)/C(=C/c3ccc(-c4ccc(Br)cc4C(=O)O)o3)C2=O)c1	IC50	'='	32100.0	nM	Inhibition of human cathepsin B
Cc1cncc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	652.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@H](Cc2ccccc2)NC(=O)c2ccncc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CCC(NC(=O)c1ccc(OCc2ccccn2)c(C(F)(F)F)c1Cl)C(=O)C(=O)Nc1ccn(C)n1	IC50	'='	3236.0	nM	Inhibition of human cathepsin B by fluorescence assay
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)C1(c2ccccc2)CC1	IC50	'>'	10000.0	nM	Inhibition of human Cat B in HepG2 cells
CCC[C@@H](C=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C	IC50	'='	9500.0	nM	Compound was tested for inhibition of human liver Cathepsin B
CC[C@@H](C)[C@H](NC(=O)Nc1cccc(C)c1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	270.0	nM	Inhibition of human cathepsin B
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NCC(=O)N1CCN(C)CC1	IC50	'='	544.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cccc2ccccc12)C(=O)C(=O)NCC(=O)N1CCN(C)CC1	IC50	'='	540.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
NC(=S)N/N=C(\c1ccc(C(F)(F)F)cc1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CCC(NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(=O)c1cccc(Cl)c1)C(=O)c1nc2ccccc2o1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin-B
O=C(N[C@@H](Cc1cccs1)C(=O)N[C@@H]1C(=O)N2CCS(=O)(=O)[C@@H]12)OCc1ccccc1	IC50	'='	430.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
Cc1cccc(C[C@H](Nc2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(O)c2)c1	IC50	'>'	1000.0	nM	Inhibitory activity against cathepsin B (catB)
CC(C)C[C@H](NC(=O)c1ccc(-c2ccccc2)cc1)C(=O)NC1(C#N)CC1	IC50	'='	1721.0	nM	Inhibition of human cathepsin B
N#CN1CC[C@@H](NS(=O)(=O)c2cc(Br)ccc2Br)C1	IC50	'='	1584.89	nM	Inhibition of human recombinant cathepsin B after 1 hr
COc1ccc(OC)c(S(=O)(=O)N[C@@H]2C[C@@H](C)N(C#N)C2)c1	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
NC(=S)N/N=C1\CCSc2c(F)cc(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCSc2ccc(OC(F)(F)F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCSc2ccc3ccccc3c21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)NN=C1CCS(=O)(=O)c2ccc(O)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CCCC[C@@H](C=O)NC(=O)O[C@@H](C)CC1CCCCC1	IC50	'='	400.0	nM	Inhibitory concentration against recombinant human cathepsin B was determined in a fluorescence assay using 10 uM Cbz-Phe-Arg-AMC as substrate
CC(NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)[PH](=O)C(Oc1ccccc1)Oc1ccccc1	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CC(C)C[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	178.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(F)cc2C(F)(F)F)CN1c1cc(C)nn1C1CCC1)C(=O)C(=O)NC1CC1	IC50	'='	2918.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)C[C@H](NC(=O)OCC(C)(C)Sc1ccccc1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O	IC50	'='	1900.0	nM	Inhibition of human Cathepsin B
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]3CCCNC3=O)C(=O)COC(=O)c3c(C(F)(F)F)cccc3C(F)(F)F)cc12	IC50	'='	464.0	nM	Inhibition of human cathepsin B incubated for 30 mins by fluorometric analysis
N#CCNC(=O)C1CCCCC1CSc1cccc(Cl)c1	IC50	'='	102000.0	nM	Inhibition of cathepsin B
Cc1ccc(/C(=N\NC(N)=S)c2cccc(Br)c2)cc1	IC50	'='	5690.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1c(F)cccc1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
COc1ccc(OC)c(S(=O)(=O)N[C@@H]2CCN(C#N)C2)c1	IC50	'='	12589.25	nM	Inhibition of human recombinant cathepsin B after 1 hr
CCCc1cc(-c2ccc(F)c(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
O=C(Nc1ccc2c(c1)C(=O)C(=O)c1ccccc1-2)c1ccccc1F	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(Cl)c(Cl)c2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	8507.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(/c1ccccc1)c1cccnc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
NC(=S)N/N=C(\c1cccnc1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
NC(=S)N/N=C(\c1ccc(Br)nc1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	953.0	nM	Inhibition of cathepsin B
O=CN1CC[C@@H](NS(=O)(=O)c2cccc(Br)c2)C1	IC50	'>'	25118.86	nM	Inhibition of human recombinant cathepsin B after 1 hr
COc1cccc(/C=C/C(=O)NC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CN1C(=O)[C@]2(N=C1N)c1cc(-c3cccnc3F)ccc1O[C@]1(C)CCCO[C@H]12	IC50	'='	1800.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C3CNCCO3)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc3cc[nH]c3c2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CCCC[C@H](NC(=O)O[C@@H]1C(=O)OCC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	500.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
NC(=S)N/N=C(\c1ccc(Br)cc1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CC(C)c1cc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)n(C)n1	IC50	'='	5011.87	nM	Inhibition of cathepsin B
N#CN1CCC(COCc2ccccc2)C1	IC50	'='	1100.0	nM	Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate
Cc1ccc(C)n1-c1ccc(CC(=O)O)cc1	IC50	'='	10100.0	nM	Inhibition of human cathepsin B
CS(=O)(=O)c1ccc(-c2ccc([C@H](N[C@@H](Cc3ccccc3)C(=O)N[C@H](C#N)Cc3ccccc3)C(F)(F)F)cc2)cc1	IC50	'='	577.0	nM	Inhibition of human Cat B in HepG2 cells
CS(=O)(=O)c1ccc(-c2ccc([C@H](N[C@H](C(=O)N[C@H](C#N)Cc3ccccc3)C3CC3)C(F)(F)F)cc2)cc1	IC50	'='	68.0	nM	Inhibition of human Cat B in HepG2 cells
Cn1nc(C(C)(C)C)cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N	IC50	'='	6309.57	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
Cc1ccc(/C(=N/NC(N)=S)c2cccc(F)c2)cc1	IC50	'='	4500.0	nM	Inhibition of human cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)C1CCCCCC1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
COc1cc(O)ccc1/C=C/C(=O)c1ccc(F)cc1	IC50	'='	95090.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
Cc1noc(C)c1CN1CCC(CCOc2ccc(-c3cc4c(ncn4C)c(C#N)n3)cc2C(F)(F)F)CC1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
Cc1noc(CN2CCC(CCOc3ccc(-c4cc5c(ncn5C)c(C#N)n4)cc3C(F)(F)F)CC2)n1	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)CN2C(=O)c2ccccc2)CC1	IC50	'>'	25000.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CS(=O)(=O)N1CCc2c(c(-c3ccc(Cl)c(C#Cc4ccc(Cl)cc4)c3)nn2CCCN2CCOCC2)C1	IC50	'>'	20000.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1ccccc1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C1\CCN([N+](=O)[O-])c2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCNc2ccccc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
NC(=S)N/N=C1\CCCS(=O)(=O)c2cc(F)c(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CCC(NC(=O)c1cccc(C(F)(F)F)c1Cl)C(=O)C(=O)Nc1cc[nH]n1	IC50	'='	5754.0	nM	Inhibition of human cathepsin B by fluorescence assay
CC(NC(=O)c1ccc(OCc2ccccn2)c(C(F)(F)F)c1Cl)C(=O)C(=O)Nc1ccn(C)n1	IC50	'='	15136.0	nM	Inhibition of human cathepsin B by fluorescence assay
CCC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@H](C=O)C(C)C	IC50	'='	120.0	nM	Inhibition of human cathepsin B
CC[C@H](C(=O)N[C@H]1CCN(CC(=O)NC/C=C/S(C)(=O)=O)C1=O)c1cc(Cl)cc(Cl)c1	IC50	'>'	100000.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
O=C(N[C@@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H]1C(=O)N2CCS(=O)(=O)[C@@H]12)OCc1ccccc1	IC50	'='	390.0	nM	Inhibitory activity of Cbz-Phe-Arg-AMC against Cathepsin B cysteine protease
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C12CC3CC(CC(C3)C1)C2)C(=O)C(=O)NCC(=O)N1CCN(C)CC1	IC50	'>'	2500.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccnc2ccccc12)C(C)(C)C)C(=O)C(=O)NCC(=O)N1CCN(C(C)C)CC1	IC50	'>'	2500.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CCCC[C@H](NC(=O)OC1C[C@H](C)C[C@@H](C)C1)C(=O)C(=O)N[C@H](C)c1ccccc1	IC50	'>'	13000.0	nM	Inhibitory concentration against human cathepsin B by fluorescence assay using 10 uM Cbz-Phe-Arg-AMC
CC[C@H](C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CS(=O)(=O)Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@H](/C=C/S(C)(=O)=O)CC(C)C	IC50	'>'	150000.0	nM	Inhibition of cathepsin B
CCNC(=O)C(=O)C(Cc1ccc(Br)cc1)NC(=O)[C@H](CC(C)C)NC(=O)CCCCC1CCSS1	IC50	'='	650.0	nM	Inhibitory activity against cathepsin B
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc(C4CC4)cs3)CC2)CC1	IC50	'='	5011.87	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CC1(C)COCc2sc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)CC3)nc21	IC50	'='	2511.89	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
N#Cc1nc(NCc2cccc(-c3ccc4cc[nH]c4c3)c2)c2ncn(CCCO)c2n1	IC50	'='	13000.0	nM	Inhibition of human liver cathepsin B
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nccs3)CC2)CC1	IC50	'='	2511.89	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
Cc1sc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)nc1C(F)(F)F	IC50	'='	5011.87	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CCCC(CCC)S(=O)(=O)C[C@@H](NC(=O)OCc1cccnc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	369.0	nM	Inhibition of cathepsin D
CS(=O)(=O)c1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)cc1	IC50	'='	2400.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
COc1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NCC#N)CC2)cc1	IC50	'='	399.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#CCNC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCN(c2ccc(F)cc2)CC1	IC50	'='	315.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
COc1ccc(/C=C/C(=O)c2ccc(O)cc2O)cc1Br	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
COc1cccc2c3c([nH]c12)CCN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)C3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CC(C)(C)[Si](C)(C)Oc1cc(Br)cc(/C(=N\NC(N)=S)c2cccc(Br)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
NC(=S)N/N=C(/c1cccc(Br)c1)c1cc(Br)cs1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3ccccc3)CC2)CC1	IC50	'='	1440.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#Cc1nc(NC[C@@H](O)c2ccccc2)nc(N2CCOCC2)n1	IC50	'='	19000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CCCCNC(=O)C(=O)[C@H](CCC)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1	IC50	'='	172.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#Cc1nc(CCCN2CCCCC2)cc(-c2cccc(C(F)(F)F)c2)n1	IC50	'='	4200.0	nM	Inhibition of human recombinant cathepsin B by fluorescence assay
NC(=S)N/N=C(\c1cccc(F)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(\c1cc(Cl)cc(Cl)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
COc1ccccc1/C=C/C=C/C(=O)c1ccc(O)cc1	IC50	'='	33060.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
COc1ccc(/C=C/C(=O)c2ccc(O)cc2)c2ccccc12	IC50	'='	14550.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
CS(=O)(=O)c1cccc2c3c([nH]c12)CCN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)C3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CC(C)(C)[C@@H](C#N)NC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCc2[nH]c3ccc(F)cc3c2C1	IC50	'='	31200.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CCCc1cc(-c2cccc(C(C)C)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	251.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)N[C@@H](C)C(=O)N1CCN(C)CC1	IC50	'>'	2500.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)[C@@H]3C[C@@H](O)CCN3)cc2)cc1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin)
C[C@]12CCCO[C@@H]1[C@]1(CSC(N)=N1)c1cc(-c3cc(F)cc(Cl)c3)ccc1O2	IC50	'='	34000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(C)=CCC/C(C)=C\Cc1c(O)cc(O)c(C(=O)CCc2ccc(O)cc2)c1O	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using fluorometric Z-Phe-Arg-AMC as substrate by spectrofluorimetry
CC(C)=CCc1cc(CCC(=O)c2c(O)cc3c(c2O)CCC(C)(C)O3)ccc1O	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using fluorometric Z-Phe-Arg-AMC as substrate by spectrofluorimetry
N#Cc1nc(NCc2ccccc2)c2ncn(CC3CCCCO3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
Cc1ccc(CNc2nc(C#N)nc3c2ncn3Cc2ccccc2)cc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCn1cnc2c(NCc3ccc(OC)cc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
Cc1cccc(CNc2nc(C#N)nc3c2ncn3Cc2ccccc2)c1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(F)cc2)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	7280.0	nM	Inhibition of human cathepsin B
Cc1cccc(CNc2nc(C#N)nc3c2ncn3C2CCCC2)c1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CC(Nc1nc(C#N)nc2c1ncn2C1CCCC1)c1ccccc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCCCNc1nc(C#N)nc2c1ncn2Cc1ccccc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(Cc3cccc(C(F)(F)F)c3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)Cc2cccc(F)c2F)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	1844.0	nM	Inhibition of human cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	7740.0	nM	Inhibition of human cathepsin B
N#CCNC(=O)C1CCCCC1CSc1ccccc1	IC50	'='	5300.0	nM	Inhibition of cathepsin B
NC(=S)N/N=C(\c1cccc(O)c1)c1cc(Br)cc(C(=O)c2cccc(O)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCN=C(N)N	IC50	'='	4.6	nM	Inhibition of cathepsin B (unknown origin) using Cbz-Phe-Arg-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by fluorometric assay
NC(=S)N/N=C1\CCSc2ccc(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CCc1ccc2c(c1)/C(=N/NC(N)=S)CCS2	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCSc2ccc(C(F)(F)F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCSc2ccc(O)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCS(=O)(=O)c2cc(F)c(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCS(=O)(=O)c2c(F)cc(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCS(=O)(=O)c2c(Br)cc(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C1\CCS(=O)(=O)c2ccc(C(F)(F)F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CCc1csc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)n1	IC50	'='	3162.28	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CC(C)(C)c1csc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)n1	IC50	'='	3162.28	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
NC(=S)N/N=C1\CCSc2c(OC(F)(F)F)cccc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)N/N=C(\c1cc(Br)cc(C(=O)c2ccccc2F)c1)c1ccccc1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
COc1ccccc1/C=C/C=C/C(=O)c1cccnc1	IC50	'='	33270.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
FC(F)(F)c1cccc(Nc2nc(Nc3ccc(-c4ccsc4)cn3)ncc2Cl)c1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate pretreated for 60 mins followed by substrate addition incubated for 30 mins
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(F)cc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	139.7	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CN1C(=O)[C@]2(N=C1N)c1cc(-c3cccnc3F)ccc1O[C@@]1(C)CCCO[C@@H]12	IC50	'='	6600.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1cccc2ccccc12)C(C)(C)C)C(=O)C(=O)NC1CCCCC1	IC50	'='	721.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CCOC(=O)/C=C/C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1	IC50	'='	70.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
[N-]=[N+]=CC(=O)N(Cc1ccccc1)C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	2000.0	nM	Inhibition of cathepsin-B using Z-Arg-Arg AMC as substrate by fluorescence assay
CC(C)(NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	25000.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CS(=O)(=O)c1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NCC#N)CC2)cc1	IC50	'='	1180.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4ncccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4c(C(F)(F)F)cccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#Cc1cccc2c3c([nH]c12)CCN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)C3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
COc1cc(/C=C/C=C/C(=O)c2ccc(O)cc2)ccc1O	IC50	'='	11050.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
O=C(/C=C/c1ccc(O)c2ccccc12)c1ccco1	IC50	'>'	50000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	312.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(C3(C(N)=O)CC3)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	27.0	nM	Inhibition of human Cat B in HepG2 cells
NC(=S)NN=C1c2cc(Br)ccc2-c2ccc(Br)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CC(C)C[C@@H](C(=O)NCC#N)c1cccc(-c2ccc(N3CCNCC3)cc2)c1	IC50	'='	4400.0	nM	Inhibitory activity against human cathepsin B expressed in HepG2 cells
COC(=O)CC(NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C(=O)CF	IC50	'='	300.0	nM	Compound was evaluated for its inhibitory activity against Cathepsin B
COc1cc(/C=C/C=C/C(=O)c2ccc(O)cc2)ccc1O	IC50	'='	3810.0	nM	Inhibition of cathepsin B in human SH-SY5Y cells using RR-AMC as substrate by fluorescence microplate reader assay
CSc1ccc(/C=C2\N=CN(NS(=O)(=O)c3ccc(Cl)c(C(=O)O)c3)C2=O)cc1	IC50	'='	63100.0	nM	Inhibition of human cathepsin B
O=C(O)c1cc(Cl)ccc1-c1ccc(/C=c2\sc3nc(=O)c4c5c(sc4n3c2=O)CCCC5)o1	IC50	'='	59400.0	nM	Inhibition of human cathepsin B
C[S+]([O-])C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	9724.0	nM	Inhibition of human cathepsin B
CSC[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	417.0	nM	Inhibition of human cathepsin B
CCCCCCNc1nc(C#N)nc2c1ncn2C1CCCC1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(/c1cccc(Br)c1)c1cccc(Br)c1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
Cc1ccc(/C(=N\NC(N)=S)c2ccc(Br)cc2)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(\c1ccc(F)cc1)c1ccccc1F	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NCC(=O)N1CCN(C)CC1	IC50	'>'	2500.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1cccc2ccccc12)C(C)(C)C)C(=O)C(=O)NCc1ccc(S(N)(=O)=O)cc1	IC50	'='	532.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NC1CCCCC1	IC50	'='	17.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)CO[C@H]1CCN2C[C@H]1OC2=O	IC50	'='	8.0	nM	Inhibition of human recombinant cathepsin B
Cc1cccc(OCC2CN(C)C(=O)O2)c1C	IC50	'>'	100000.0	nM	Inhibition of human recombinant cathepsin B
Cc1cc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)c(C)s1	IC50	'='	1995.26	nM	Inhibition of cathepsin B
C[C@]12CCCO[C@@H]1[C@]1(COC(N)=N1)c1cc(-c3cccnc3F)ccc1O2	IC50	'='	33000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CC(=O)c1c(Nc2ccc(Br)cc2Br)[nH]c2c(Cl)ccc(C)c2c1=O	IC50	'='	1750.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1	IC50	'>'	10000000.0	nM	Inhibition of human Cathepsin B
N#Cc1nc(NCc2cccc(-c3cccc(Cl)c3)c2)c2ncn(CCCO)c2n1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NC[C@H](O)c2ccccc2)nc(N2CCOCC2)n1	IC50	'='	32000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
Cc1cccc(C[C@H](Nc2ccc3c(c2)C(=O)N(C)C3=O)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	4.9	nM	Inhibitory activity against cathepsin B (catB)
Cc1cccc(C[C@H](Nc2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(-n3cnnn3)c2)c1	IC50	'='	16.5	nM	Inhibitory activity against cathepsin B (catB)
CC(C)C[C@H](NC(=O)OCC(C)(C)Oc1cccc(Cl)c1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O	IC50	'='	900.0	nM	Inhibition of human Cathepsin B
COc1ccc(/C(=N/NC(N)=S)c2cccc(/C(=N/NC(N)=S)c3ccc(O)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
COC1=CC(=O)N(C(=O)/C=C/[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C2CCN(C)CC2)[C@H]1Cc1c[nH]c2ccccc12	IC50	'='	4.16	10^-4microM	Inhibition of human recombinant Cathepsin B assessed remaining activity using Z-FR-AMC as substrate incubated for 30 mins by fluorometric assay
COc1ccc(-c2ccc(S(=O)(=O)N3CCC[C@H]3C(=O)N[C@H](C#N)CC(N)=O)cc2)cc1	IC50	'>'	50000.0	nM	Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC fluorogenic substrate
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4ncccc4s3)CC2)CC1	IC50	'='	3981.07	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
COc1ccc(/C=C/C(=O)NC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1OC	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
COc1cccc(/C=C/C(=O)NC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)c1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
NC(=S)NN=C(c1cc(O)cc(Br)c1)c1cc(O)cc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin-B using Z-RR-AMC as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by fluorometric method
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)CC(F)(F)F	IC50	'='	668.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)[C@H](N[C@@H](c1ccc(-c2ccc([C@@H](O)C(F)F)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccc(C#N)cc1F	IC50	'='	87.0	nM	Inhibition of human Cat B in HepG2 cells
CCC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@H](C=O)Cc1ccccc1	IC50	'='	1400.0	nM	Inhibition of human cathepsin B
CC(C)(NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1)C(N)=O	IC50	'='	2512.0	nM	Inhibition of human recombinant cathepsin B
N#Cc1ccc(Nc2nc(C#N)nc(N3CCNCC3)n2)cc1	IC50	'='	57.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
N#Cc1nc(NC[C@H](O)c2ccccc2)nc(NC2CCCCC2)n1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CCCc1cc(-c2ccc(OC(C)C)c(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCC(C)C	IC50	'='	61.6	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
Cc1cccc(C[C@H](NC(=O)c2ccc(F)cc2F)C(=O)N[C@H](C#N)COCc2ccccc2)c1	IC50	'='	42.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
CC(NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)c1nc2ccccc2s1	IC50	'='	19000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CCNC(=S)NN=C(c1cccc(Br)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#CC1(NC(=O)[C@@H]2Cc3ccc(c(Cl)c3)OCCCCOc3cc(C(F)(F)F)ccc3C(=O)N2)CC1	IC50	'='	9000.0	nM	Inhibition of human cathepsin B
Cc1nnc(C)c2cc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)[C@H](C)C3)ccc12	IC50	'='	2940.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
COc1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)[C@H](C)C2)cc1OC	IC50	'='	1850.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
Cc1cccc(C[C@H](Nc2ccc3c(c2)C(=O)OC3)C(=O)N[C@H](C#N)COCc2ccc(F)c(C(=O)O)c2)c1	IC50	'='	4.1	nM	Inhibitory activity against cathepsin B (catB)
COc1ccc(/C(=N/NC(N)=S)c2cccc(C(=O)c3ccc(O)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
CCCC[C@@H](C=O)NC(=O)OC1(Cc2ccccc2)CCC1	IC50	'='	3400.0	nM	Inhibitory concentration against recombinant human cathepsin B was determined in a fluorescence assay using 10 uM Cbz-Phe-Arg-AMC as substrate
CCCC[C@H](NC(=O)O[C@H](Cn1cc(-c2ccc(C(F)(F)F)cc2)cn1)C(C)(C)C)C(=O)C(=O)Nc1ccn[nH]1	IC50	'='	10000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
CC(NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)c1nc2ncccc2o1	IC50	'='	59000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
CC(C)CC(C(=O)NCC#N)c1ccc(-c2ccccc2)cc1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(NC(=O)[C@H](CC(=O)N(C)C)NC(=O)[C@@H](NC(=O)CC(C)(C)C)C(C)(C)C)C(=O)c1nc2ccccc2o1	IC50	'>'	300000.0	nM	Activity against serine protease human liver Cathepsin B (cat-B )
NC(=S)N/N=C1\CCSc2c(Br)cc(F)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
NC(=S)NN=C1CCSc2ccc(N)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc(-c4ccccc4)cs3)CC2)CC1	IC50	'='	3981.07	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CS(=O)(=O)c1ccc2nc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)CC3)sc2c1	IC50	'='	7943.28	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4cnccc4s3)CC2)CC1	IC50	'='	3162.28	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
COc1ccc(/C(=N/NC(N)=S)c2cccc(C(=O)c3ccc(O)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O	IC50	'='	25000.0	nM	In vitro inhibitory activity against Cathepsin B
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Br)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	45.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCCc1ccccc1	IC50	'='	30.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)C[C@H](C)N1C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1	IC50	'='	24900.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
C[C@@H]1CN(c2ccccc2)CCN1C(=O)[C@@H]1CCCC[C@H]1C(=O)NCC#N	IC50	'='	462.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc3[nH]ccc3c2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
CC(C)CN(NC(=O)OCc1ccccc1)C(=O)CN(Cc1ccccc1)/N=C/c1cccc(B(O)O)c1	IC50	'>'	1000000.0	nM	Inhibitory concentration against Cathepsin B activity
NC(=S)N/N=C(/c1ccccc1)c1cccc(C(O)c2ccccc2)c1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
FC(F)(F)c1cccc(Nc2nc(Nc3ccc(N4CCNCC4)cn3)ncc2Cl)c1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate pretreated for 60 mins followed by substrate addition incubated for 30 mins
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2C(F)(F)F)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CC1	IC50	'='	143.6	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
CC(C)=CC[C@H]1C[C@@]2(CC=C(C)C)C(=O)C(C(=O)c3ccccc3)=C(O)[C@H](C2=O)C1(C)C	IC50	'='	103500.0	nM	Inhibition of cathepsin B by spectrofluorimetry
N#CCNC(=O)[C@H](Cc1cccc(I)c1)NC(=O)C(c1ccccc1)c1ccccc1	IC50	'='	121.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
NC(=S)N/N=C1\CCNc2c1cc([N+](=O)[O-])cc2[N+](=O)[O-]	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCN=C(N)N	IC50	'='	5.0	nM	Inhibition of human cathepsin B
CC(C)(C)[Si](C)(C)Oc1ccc(/C(=N\NC(N)=S)c2cccc(Br)c2)cc1Br	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CC(C)CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)O)C(C)C)C(C)C	IC50	'='	4260.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CN(C)CCOc1ccc(C(=O)NCc2ccnc(C#N)n2)cc1C(=O)C(C)(C)c1cc(Cl)cc(Cl)c1	IC50	'='	81000.0	nM	Inhibition of human recombinant Cathepsin B using fluorogenic peptide substrate
NC(=S)N/N=C(\c1cccc(Br)c1)c1cc(Br)cc(C(=O)c2cccc(Br)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCCOC	IC50	'='	85.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#Cc1cnc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)s1	IC50	'='	3981.07	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CCCc1cc(-c2ccc(OC(F)(F)F)c(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CC(C)[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccc(C#N)cc1F	IC50	'='	143.0	nM	Inhibition of human Cat B in HepG2 cells
CC(NC(=O)c1ccc(OCc2ccccn2)c(C(F)(F)F)c1Cl)C(=O)C(=O)N(C)C	IC50	'>'	10000.0	nM	Inhibition of human cathepsin B by fluorescence assay
NC(=S)N/N=C(/c1cccc(Br)c1)c1sccc1Br	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4c(s3)COCC4)CC2)CC1	IC50	'='	3162.28	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
NC(=S)N/N=C(/c1ccccc1)c1cccc(O)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
NC(=S)N/N=C(/c1cccc(Br)c1)c1ccc2c(c1)CCCC2	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
C[C@@H](C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC(C#N)(C1CC1)C1CC1)C(F)(F)F	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC(C)(C)C#N	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	280.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
N#C[C@@]1(NC(=O)[C@@H](N)Cc2cccs2)C[C@@H]1c1ccccc1.O=C(O)C(F)(F)F	IC50	'>'	50000.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
CCC[C@H](NC(=O)C(CC(C)C)NC(=O)c1ccc(-c2ccc(I)cc2)cc1)C(=O)C=[N+]=[N-]	IC50	'='	65.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
N#Cc1nc(NCc2ccccc2)c2ncn(Cc3ccccc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCC(C)CNc1nc(C#N)nc2c1ncn2Cc1ccccc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
COC(CCn1cnc2c(NCc3ccc(Cl)c(Cl)c3)nc(C#N)nc21)OC	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Br)cc2)c2ncn(CCCc3ccccc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
COc1ccc(Cn2cnc3c(NCc4ccc(Cl)cc4)nc(C#N)nc32)cc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(CCCO)c2n1	IC50	'='	1040.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(Cc3cccnc3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCn1cnc2c(NCc3ccc(F)cc3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(N3CCN(C(=O)OC(C)(C)C)CC3)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
N#Cc1ccc(-c2ccc(C[C@@H](C#N)NC(=O)C3(N)CCOCC3)cc2)cc1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B (unknown origin)
CCCCS(=O)(=O)C[C@@H](NC(=O)OCc1ccncc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	383.0	nM	Inhibition of cathepsin D
CCCCS(=O)(=O)C[C@@H](NC(=O)OCc1cccnc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1	IC50	'='	444.0	nM	Inhibition of cathepsin D
N#CC1(NC(=O)[C@H](CS(=O)(=O)Cc2ccc(F)cc2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	2777.0	nM	Inhibition of human cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	1104.0	nM	Inhibition of human cathepsin B
O=C(/C=C/c1ccc(N2CCCC2)cc1)c1ccc(O)cc1	IC50	'='	1810.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
N=C(N)N/N=C1\CCS(=O)(=O)c2ccc([N+](=O)[O-])cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2cn[nH]c2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	59.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'='	163.0	nM	Inhibition of human Cat B in HepG2 cells
CC(C)(C)[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human Cat B in HepG2 cells
N#CN1CC[C@@H](NS(=O)(=O)c2cccc(Br)c2)C1	IC50	'='	6309.57	nM	Inhibition of human recombinant cathepsin B after 1 hr
CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1	IC50	'='	4750.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
O=C(NCc1cccs1)[C@@H]1CN(C(=O)c2cccnc2)CCN1c1ccc(Cl)c(Cl)c1	IC50	'='	50000.0	nM	Inhibition of human Cathepsin B using Z-Leu-Arg-AMC as fluorogenic substrate incubated for 60 mins by FRET assay
N#Cc1nc(NCCc2ccccc2)nc(NC2CCCCC2)n1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CCOC(=O)/C=C/[C@@H](O)[C@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)N1CCOCC1	IC50	'='	1130.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CCCCNC(=O)C(=O)[C@H](CC)NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1	IC50	'='	47.8	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#CC1(NC(=O)[C@@H](Cc2cccnc2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'>'	50000.0	nM	Inhibition of human cathepsin B
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	IC50	'>'	30000.0	nM	Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate by spectrofluorometer analysis
CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCN=C(N)N	IC50	'='	40.0	nM	Inhibition of cathepsin B (unknown origin) using fluorometric Z-Phe-Arg-AMC as substrate by spectrofluorimetry
CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	IC50	'='	4400.0	nM	Inhibition of human Cathepsin B
CC(C)C(Nc1ccccc1)C(=O)N1CCCCN1C#N	IC50	'='	53.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2cc(C(F)(F)F)ccc2Cl)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
Cc1ccc(C)n1-c1ccc(C(=O)O)c(O)c1	IC50	'='	55000.0	nM	Inhibition of human cathepsin B
CC[C@H](C)[C@H](NC(=O)[C@H]([C@@H](C)CC)N(C)C(C)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1)[C@@H](C)O	IC50	'='	120000.0	nM	Inhibition of cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@@H](C#N)Cc1ccccc1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
NC(=S)N/N=C(/CCc1ccccc1)c1ccccc1	IC50	'>'	25000.0	nM	Inhibition of human cathepsin B
Cc1ccc(/C(=N\NC(N)=S)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1	IC50	'='	3300.0	nM	Inhibition of human cathepsin B
N#C[C@@]1(NC(=O)C(N)Cc2sccc2F)C[C@@H]1c1ccccc1.O=C(O)C(F)(F)F	IC50	'>'	50000.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
NC(=S)NN=C(c1ccc(F)cc1)c1ccc(F)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
N#CCNC(=O)[C@H](Cc1cccc(Cl)c1)NC(=O)c1ccccc1	IC50	'='	5011.87	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C	IC50	'='	6200.0	nM	Inhibition of human CatB after 60 mins fluorescence assay
Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	282.0	nM	Inhibition of human cathepsin B
CCCC[C@@H](CC)COC(=O)c1ccccc1C(=O)OC[C@@H](CC)CCCC	IC50	'='	380000.0	nM	Inhibition of cathepsin B
CCCC[C@@H](C#N)n1cc([C@@](C)(NC(=O)c2ccsc2)C2CCCCC2)nn1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
O=c1c2c(O)c(O)c(O)cc2nc(-c2ccccc2)n1-c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human Cathepsin B using fluorogenic substrate by FRET-based assay
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]3CCCNC3=O)C(=O)COC(=O)C3(C(F)(F)F)CCCCC3)cc12	IC50	'='	2854.0	nM	Inhibition of human cathepsin B incubated for 30 mins by fluorometric analysis
CSc1cccc2c3c([nH]c12)CCN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)C3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4c(Br)cccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
COc1ccc2[nH]c3c(c2c1)CN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)CC3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4ccc(Cl)cc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4c(F)cccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CN1CCN(C(=O)[C@@H]2CCCC[C@H]2C(=O)NCC#N)CC1	IC50	'='	7630.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CCNC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCc2ccccc2C1	IC50	'='	712.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CCNC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CC=CCC1	IC50				Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
COc1ccc(/C=C/C(=O)NC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)cc1OC	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(F)(F)F	IC50	'>'	900000.0	nM	Compound was tested for inhibition of human liver Cathepsin B
Cc1ccc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NCC#N)CC2)cc1	IC50	'='	572.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3ccc(F)cc3)CC2)CC1	IC50	'='	1090.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)NC(C=O)Cc1ccccc1	IC50	'='	100.0	nM	Inhibitory activity against cathepsin B
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Br)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	150.3	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3)C[C@H]2C(=O)N2CC3(COC3)C2)CC1	IC50	'='	29700.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C(=O)CF	IC50	'='	300.0	nM	Inhibition of recombinant human cathepsin B (332 residues) expressed in CHO cells using Z-FR-AMC as substrate preincubated for 20 mins followed by substrate addition by fluorescence plate reader analysis
O=C(/C=C/c1ccc(N2CCCC2)cc1)c1ccc(O)cc1O	IC50	'='	28670.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
COc1cc(O)ccc1/C=C/C(=O)c1ccc(O)cc1	IC50	'='	57680.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	1034.0	nM	Inhibition of cathepsin B
CC(C)CNc1nc(C#N)nc(N2CCOCC2)c1N	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
CC1(C)CCc2cc(CCC(=O)c3c(O)cc4c(c3O)CCC(C)(C)O4)ccc2O1	IC50	'='	14900.0	nM	Inhibition of cathepsin B (unknown origin) using fluorometric Z-Phe-Arg-AMC as substrate by spectrofluorimetry
CCCCOC(=O)c1ccccc1C(=O)OCCCC	IC50	'='	420000.0	nM	Inhibition of cathepsin B
NC(=S)N/N=C(/CCc1ccccc1)c1cccc(Cl)c1	IC50	'='	6000.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C(/C=C/c1ccccc1)c1cccc(C(F)(F)F)c1	IC50	'='	1700.0	nM	Inhibition of human cathepsin B
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C(=O)CO)cc12	IC50	'='	1300.0	nM	Inhibition of human cathepsin B
C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C(=O)C=[N+]=[N-]	IC50	'='	9400.0	nM	Inhibition of cathepsin-B using Z-Arg-Arg AMC as substrate by fluorescence assay
CC(C)C[C@@H](C(=O)NCC#N)c1cccc(-c2ccc(N3CCNCC3)cc2)c1	IC50	'='	3950.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
N#CC1(NC(=O)[C@@H]2C[C@@H](S(=O)(=O)c3ccccc3Cl)CN2C(=O)c2ccccc2)CC1	IC50	'='	35200.0	nM	Inhibition of human cathepsin-B using Z-Val-Val-Arg-AMC as substrate up to 20 mins by fluorescence assay
CCCc1cc(-c2ccc(OCC)c(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
N#Cc1nc(NCc2ccc(Cl)cc2)c2ncn(CC3CCCCC3)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCn1cnc2c(NCc3cccc(C)c3)nc(C#N)nc21	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCCCCCNc1nc(C#N)nc2c1ncn2CCCC	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
N#Cc1nc(NC2CCCCC2)c2ncn(C3CCCCC3)c2n1	IC50	'='	23600.0	nM	Inhibition of human liver cathepsin B
CCCn1cnc2c(NC3CCCCC3)nc(C#N)nc21	IC50	'='	19050.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(\c1ccc(F)cc1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
NC(=S)N/N=C(\c1ccc(F)cc1)c1ccc(Br)cc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B
CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)[C@@H](C)CC	IC50	'='	7560.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	1050.0	nM	Inhibition of cathepsin B in human HepG2 cells
N#Cc1nc(NCc2cccc(-c3cc4ccccc4n3S(=O)(=O)c3ccccc3)c2)c2ncn(CCCO)c2n1	IC50	'>'	50000.0	nM	Inhibition of human liver cathepsin B
CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCCCN=C(N)N	IC50	'='	16.0	nM	Inhibition of human cathepsin B
Cc1cc(NC(=O)Cn2nnc(-c3ccc(NC(=O)c4ccc(F)cc4)cc3)n2)no1	IC50	'='	37140.0	nM	Inhibition of human cathepsin B
CO[C@@H](C)c1c(NC(=O)Nc2cnc(-n3nccn3)c(Cl)c2)cnc2cc(Cl)nn12	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin)
COc1ccc(C(=O)Nc2ccc3nc(SCC(=O)c4ccccc4)sc3c2)cc1	IC50	'='	17660.0	nM	Inhibition of human cathepsin B
CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](/C=C/S(=O)(=O)c1ccccc1)CCc1ccccc1	IC50	'='	1360.0	nM	Inhibition of human recombinant cathepsin B after 10 mins
COC(=O)c1cccc(N[C@@H](Cc2cccc(C)c2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	8.6	nM	Inhibitory activity against cathepsin B (catB)
Cc1ccc(C)n1-c1ccc(SCC(=O)O)cc1	IC50	'='	58300.0	nM	Inhibition of human cathepsin B
O=C(/C=C/c1ccc(N2CCCC2)cc1)c1ccc([N+](=O)[O-])cc1	IC50	'='	28950.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
O=C(/C=C/c1ccc(F)cc1)c1ccc(O)cc1O	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
COC(=O)C[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	65.0	nM	Inhibition of human cathepsin B
CC(C)C[C@@H](C(=O)NCC#N)c1cccc(-c2ccc(N3CCNCC3)cc2)c1	IC50	'='	3950.0	nM	Inhibitory concentration against human cathepsin B
Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21	IC50	'>'	20000.0	nM	Inhibition of human recombinant cathepsin B
CC(C)C[C@@H](C=O)NC(=O)[C@@H]1Cc2ccc(cc2)Oc2cc(ccc2[N+](=O)[O-])C[C@H](NC(=O)OCc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N1	IC50	'='	3100.0	nM	Inhibition of human liver cathepsin B using Cbz-Arg-Arg-AMC as fluorogenic substrate measured every 20 seconds for 10 mins by fluorescence based assay
CC(C)(C)CN(Cc1ccc(-c2ccccc2)cc1)c1nccc(C#N)n1	IC50	'>'	500000.0	nM	Inhibition of Cathepsin B (unknown origin) assessed as inhibition of AFC release using sequence RR labelled with AFC as substrate by fluorescence based analysis
N#CCNC(=O)[C@H](Cc1ccccc1)NC(=O)C(c1ccccc1)c1ccccc1	IC50	'='	496.0	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
N#Cc1nc(Nc2cccc(F)c2)nc(N2CCOCC2)n1	IC50	'='	1900.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
N#Cc1nc(Nc2cccc([N+](=O)[O-])c2)nc(N2CCOCC2)n1	IC50	'='	11000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
COc1cccc(Nc2nc(C#N)nc(N3CCOCC3)n2)c1	IC50	'='	2300.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
COc1ccc(Nc2nc(C#N)nc(N3CCOCC3)n2)cc1	IC50	'='	5000.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CCC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C(=O)N[C@H](C=O)Cc1ccc(O)cc1	IC50	'='	1300.0	nM	Inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@@H](Cc2ccccc2)NC(=O)C2CCN(C(=O)OCc3ccccc3)CC2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
COc1cc(OC)cc(/C(=N\NC(N)=S)c2cc(Br)cc(Br)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin-B using Z-RR-AMC as substrate preincubated for 5 mins followed by substrate addition measured for 5 mins by fluorometric method
CC1(C)CCc2c(cc(O)c(C(=O)CCc3ccc4c(c3)CC3C(C)(C)CCCC3(C)O4)c2O)O1	IC50	'='	8500.0	nM	Inhibition of cathepsin B (unknown origin) using fluorometric Z-Phe-Arg-AMC as substrate by spectrofluorimetry
CC(C)(C)CN(Cc1ccc2ccccc2c1)c1nccc(C#N)n1	IC50	'>'	500000.0	nM	Inhibition of Cathepsin B (unknown origin) assessed as inhibition of AFC release using sequence RR labelled with AFC as substrate by fluorescence based analysis
COC1=CC(=O)N(C(=O)/C=C/[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N(C)C)[C@H]1Cc1c[nH]c2ccccc12	IC50	'='	1.49	10^-4microM	Inhibition of human recombinant Cathepsin B assessed remaining activity using Z-FR-AMC as substrate incubated for 30 mins by fluorometric assay
CCOC(=O)/C=C/C(=O)N(CC(N)=O)NC(=O)[C@@H]1CCCN1C(C)=O	IC50	'>'	1000000.0	nM	Inhibition Assay: Assay buffers consist of 20 mM citric acid, 60 mM disodium hydrogen orthophosphate, 1 mM EDTA, 0.1% CHAPS, 4 mM DTT, pH 5.8 for legumain, 50 mM dihydrogen sodium orthophosphate, 1 mM EDTA, 5 mM DTT, pH 6.25 for cathepsin B and cathepsin Land 100 mM Tris, 0.1% CHAPS, 10% sucrose, 10 mM DTT, pH 7.4 for caspase-3. Concentrations of substrates during the measurement were 10 nM (legumain, cathepsin Land caspase-3) and 50 nM (cathepsin B) and concentration of enzymes were 100 nM for cathepsin Land caspase-3, 270 nM for legumain and 360 nM for cathepsin B. Each enzyme was incubated with inhibitor concentrations ranging from 1 nM to 1 mM in the presence of the substrates.
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]3CCCNC3=O)C(=O)COC(=O)c3c(C)cc(C)nc3C)cc12	IC50	'='	201.0	nM	Inhibition of human cathepsin B incubated for 30 mins by fluorometric analysis
CCCC[C@@H](/C=N/NC(=O)N1CCOCC1)NC(=O)OC(C)(C)C	IC50	'='	32000.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)[C@@H](C)CC	IC50	'='	2.24	nM	Inhibition of cathepsin B (unknown origin) assessed as reduction in 7-amino-4-methylcoumarin formation using Z-Arg-Arg-MCA as substrate preincubated for 3 mins followed by substrate addition and measured after 10 mins by fluorescence spectrometric method
Cc1cccc(CNc2nc(C#N)nc(N3CCNCC3)n2)c1	IC50	'='	57.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccc(C#N)cc1F	IC50	'='	9.0	nM	Reversible inhibition of human cathepsin B
CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1	IC50	'='	4800.0	nM	Inhibitory activity against human cathepsin B
CC(C)C[C@@H](C(=O)NCC#N)c1cccc(-c2ccc(N3CCNCC3)cc2)c1	IC50	'='	86000.0	nM	Inhibitory activity against human cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(N3CCNCC3)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	1111.0	nM	Inhibition of Cathepsin B
NC(=S)N/N=C(/c1ccc(F)cc1)c1cccc(C(=O)c2ccc(F)cc2)c1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
COc1ccc(C(=O)c2cccc(/C(=N/NC(N)=S)c3ccc(O)cc3)c2)cc1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
CC(C)c1ccc2[nH]c3c(c2c1)CN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)CC3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
C[C@H](C#N)NC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCc2[nH]c3ccc(F)cc3c2C1	IC50	'='	44900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CCCC[C@@H](/C=N/NC(=O)N1CCOCC1)NC(=O)O[C@H](Cc1ccccc1)C(C)C	IC50	'='	18.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
COc1ccc(/C(=N\NC(N)=S)c2cc(OC)c(OC)c(OC)c2)cc1O	IC50	'='	1424.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCNC(=N)N	IC50	'='	47.0	nM	Inhibition of cathepsin B by spectrofluorimetry
CCCc1cc(-c2ccccc2C(F)(F)F)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CCCc1cc(-c2ccc(OC)c(C(F)(F)F)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
Cc1nnc(-c2cccc(C[C@H](NC(=O)c3cc(C(C)(C)C)nn3C)C(=O)NCC#N)c2)s1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CCCC[C@H](NC(=O)O[C@H](Cc1nnc(-c2ccc(C(F)(F)F)cc2)o1)C(C)(C)C)C(=O)C(=O)Nc1ccn[nH]1	IC50	'='	45000.0	nM	Inhibition of 10 lM Cbz-Phe-Arg-AMC binding to human cathepsin B activity in fluorescence assay with 100 mM NaOAc
N#CCNC(=O)[C@H](Cc1cccc(-c2cncnc2)c1)NC(=O)c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B assessed as inhibition of fluorogenic substrate cleavage
CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)NC(C=O)Cc1ccccc1	IC50	'='	1360.0	nM	Inhibition of human liver cathepsin B after 30 mins by fluorometric end-point assay
CCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NC1CCCCC1	IC50	'='	16.0	nM	Inhibition of cathepsin B (unknown origin)
CCCc1cc(-c2cccc(C3CCCC3)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
CN1CCN(c2nc(-c3ccc(C(=O)NC4(C(=O)NCC#N)CCCCC4)cc3)cs2)CC1	IC50	'='	1050.0	nM	Inhibitory activity against cathepsin B from human
CN1CCN(c2nc(-c3ccc(C(=O)NC4(C(=O)NCC#N)CCCCC4)cc3)cs2)CC1	IC50	'='	17.0	nM	Inhibitory activity against human cathepsin B expressed in HepG2 cells
Cc1noc2cc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)[C@H](C)C3)ccc12	IC50	'='	603.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
FC(F)(F)c1cccc(Nc2nc(Nc3cccc(-c4ccsc4)c3)ncc2Cl)c1	IC50	'>'	5000.0	nM	Inhibition of human recombinant Cathepsin B using Z-Leu-Arg-AMC as substrate pretreated for 60 mins followed by substrate addition and incubated for 30 mins by microplate reader assay
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	1.8	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
CN1CCN(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](/C=C/S(=O)(=O)c2ccccc2)c2ccc(-c3ccccc3)cc2)CC1	IC50	'='	300.0	nM	Inhibition of human liver cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by fluorometric method
CC(C)c1ccc2c(c1)/C(=N/NC(N)=S)CCS2	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NCC(=O)N1CCCCC1	IC50	'='	81.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1)C(=O)C(=O)NCC(=O)N1CCN(C(C)C)CC1	IC50	'>'	2500.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
Cc1ccc2c(c1)/C(=N/NC(N)=S)CCS2(=O)=O	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
COc1cc2c([nH]c3c4c(c(C)cc32)OC(C)(C)C=C4)c(-c2c(O)c(OC)cc3c2[nH]c2c4c(c(C)cc23)OC(C)(C)C=C4)c1O	IC50	'='	1.3	ug.mL-1	Inhibition of cathepsin B mediated osteoporotic activity
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)N(C)C1CC1	IC50	'='	1537.0	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
Cc1cccc(C[C@H](NC(=O)c2ccc(Cl)cc2F)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'<'	10.0	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
N#CCNC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	62000.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
N#CC1(NC(=O)[C@H](Cc2nc3ccccc3s2)NC(=O)c2ccc(-c3ccccc3)cc2)CC1	IC50	'>'	5000.0	nM	Inhibition of human cathepsin B
CC(C)[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ncc(Cl)cc2F)CC1)C(=O)C(=O)NC1CC1	IC50	'='	323.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
NC(=S)N/N=C(/c1ccc(Br)cc1)c1cccc(/C(=N/NC(N)=S)c2ccc(Br)cc2)c1	IC50	'>'	10000.0	nM	Biological Assay: Human liver Cathepsin B (Calbiochem) was pre-incubated with test compound at various concentrations for 5 minutes at 37C. The assay was initiated by addition of substrate Z-Arg-Arg-aminomethylcoumarin (Z-R-R-AMC Bacchem) and the final assay conditions were 1.1 nM cathepsin B, 60 uM Z-R-R-AMC, 126 mM sodium potassium phosphate pH 6.0 (Fisher), 0.3 mM EDTA (Omnipure), 2.7 mM DTT (Omnipure), 0.004% BRIJ 35 (Sigma), and 2.0% DMSO (Acros) in a final volume of 200 uL. Test compounds were serially diluted with DMSO and 0.01% BRIJ 35 to include a final concentration range of 20 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 37C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.
CC[C@H](N)C(=O)N[C@H](C#N)Cc1ccc(-c2ccccc2)cc1	IC50	'>'	10000.0	nM	Inhibition of Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)N[C@@H](C)C#N	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
Cc1cc(C)cc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)c1	IC50	'='	7943.28	nM	Inhibition of cathepsin B
Cc1cc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)c2cc(C)ccc2c1	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
N#Cc1nc(Nc2cccc([N+](=O)[O-])c2)nc(NC2CCNCC2)n1	IC50	'='	1700.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
C[C@]12CCCO[C@@H]1[C@]1(COC(N)=N1)c1cc(-c3cccc(C#N)c3)ccc1O2	IC50	'='	58000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
CCN(CC)C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
CCN(CC)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)COC(=O)[C@@H]1CCCN1C(C)=O)C(C)C	IC50	'>'	100.0	ug.mL-1	Inhibition of cathepsin B (unknown origin)
COc1ccc2c(c1)CCC/C2=N\NC(N)=S	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](/C=C/S(=O)(=O)c1ccccc1)CCc1ccccc1	IC50	'='	4504.0	nM	Inhibition of human cathepsin B
N#Cc1nc(NC2CCCCC2)nc(N2CCNCC2)n1	IC50	'='	520.0	nM	Inhibition of human recombinant cathepsin B by fluorescence assay
Cc1ccc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)cc1	IC50	'='	2511.89	nM	Inhibition of cathepsin B
N#CSCC(=O)N1c2ccccc2CCc2ccccc21	IC50	'>'	50000.0	nM	Inhibition of Cathepsin B (unknown origin) using Z-RR-AMC as fluorogenic substrate preincubated for 10 mins followed by substrate addition and measured for 10 mins by fluorescence based assay
Nc1ccc(Nc2nc(Nc3ccc(-c4ccsc4)cn3)ncc2Cl)cc1	IC50	'>'	5000.0	nM	Inhibition of human recombinant Cathepsin B using Z-Leu-Arg-AMC as substrate pretreated for 60 mins followed by substrate addition and incubated for 30 mins by microplate reader assay
CC(=O)N[C@@H](CC(=O)NCCC(COCc1ccccc1)COCc1ccccc1)C(=O)N[C@@H](CC(C)C)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1	IC50	'>'	30000.0	nM	Inhibition of recombinant cathepsin B (unknown origin) using Z-Leu-Arg-AMC as substrate by spectrofluorometer analysis
CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	IC50	'='	210.0	nM	Inhibition of cathepsin B
N#C[C@@]1(NC(=O)[C@@H](N)Cc2cccs2)C[C@@H]1c1ccccc1	IC50	'>'	50000.0	nM	Inhibition of human cathepsin B
Cc1nn(C)cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N	IC50	'>'	10000.0	nM	Inhibition of cathepsin B
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C#N)C[C@@H]3CCCNC3=O)cc12	IC50	'='	32000.0	nM	Inhibition of human cathepsin B
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccccc1)C(C)(C)C)C(=O)C(=O)NC1CCCCC1	IC50	'='	378.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
Cc1cccc(C(=O)c2cccc(/C(=N/NC(N)=S)c3cccc(C)c3)c2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
NC(=S)N/N=C(\c1ccccc1)c1cc(C(=O)c2ccccc2)cc(C(=O)c2ccccc2)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-RR-AMC as substrate after 5 mins by fluorescence assay
CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NC1CCOCC1	IC50	'='	188.4	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
COc1cccc(/C=C/C(=O)NC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CCC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2Cl)CN1C(=O)C1(c2ccc(Cl)cc2)CC1)C(=O)C(=O)NCC(F)(F)F	IC50	'='	366.2	nM	Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DTT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat L. Substrate (20 μM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem).Z=Benzyloxycarbonyl.AMC=7-Amino-4-Methyl-Coumarin. DTT=dithiothreitol. Final volume: 100 μL. Excitation 360 nm, Emission 465 nm.
NC(=S)N/N=C(/c1cccc(Br)c1)c1ccc(O)c(Br)c1	IC50	'='	9493.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CCOC(=O)/C=C/[C@@H](O)[C@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	23900.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
Nc1ccc2c(c1)C(=O)C(=O)c1ccccc1-2	IC50	'>'	10000.0	nM	Inhibitory concentration against Cathepsin B
C[C@]12CCCO[C@@H]1[C@]1(COC(N)=N1)c1cc(-c3cccc(C#N)c3)ccc1O2	IC50	'='	82000.0	nM	Inhibition of cathepsin D purified from human spleen after 1 hr by FRET assay
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C#N)C[C@@H]3CCNC3=O)cc12	IC50	'='	28000.0	nM	Inhibition of human cathepsin B
CS(=O)(=O)c1ccc2c3c([nH]c2c1)CCN(C(=O)[C@@H]1CCCC[C@H]1C(=O)NC1(C#N)CC1)C3	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
N#CCNC(=O)[C@@H]1CCCC[C@H]1C(=O)N1CCN(c2ccccc2)CC1	IC50	'='	455.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CC[C@@H](C)[C@H](NC(=O)c1ccccc1)C(=O)N[C@@H](C=O)Cc1c[nH]c2ccccc12	IC50	'='	52.0	nM	Inhibition of human cathepsin B
CCCc1cc(-c2cccc(C(C)(C)C)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@@H](Cc2ccccc2)NC(=O)C2CCN(C(=O)OCc3ccccc3)CC2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
Cl.O=C1C=C(Nc2ccccc2N2CCNCC2)C2=NS(=O)(=O)c3cccc1c32	IC50	'='	8800.0	nM	Inhibition of His-tagged recombinant human Cathepsin B expressed in HEK293 cells using Z-Leu-Arg-AMC as substrate incubated for 30 mins followed by substrate addition by fluorescence based analysis
N#Cc1ccccc1N1CCN(C[C@@H](O)COC[C@@H](Cc2ccccc2)NC(=O)c2ccncc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(N3CCNCC3)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	1111.0	nM	Reversible inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@H](Cc2ccccc2)NC(=O)c2ccncc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
CC(C)[C@H](N[C@@H](c1ccc(-c2ccc([C@@H](O)C(F)F)cc2)cc1)C(F)(F)F)C(=O)N[C@H](C#N)Cc1ccc(C#N)cc1F	IC50	'='	87.0	nM	Reversible inhibition of human cathepsin B
O=C(c1ccccc1)c1ccccc1	IC50	'='	288800.0	nM	Inhibition of cathepsin B by spectrofluorimetry
O=C(O)c1cc(Cc2ccc(O)c(C(=O)O)c2)ccc1O	IC50	'='	90200.0	nM	Inhibition of human cathepsin B
N#CN1CC(CNC(=O)C2CCCCC2)C1	IC50	'='	150.0	nM	Inhibition of human cathepsin B
Cc1ccc(C)n1-c1ccc(Cl)c(C(=O)O)c1	IC50	'='	7300.0	nM	Inhibition of human cathepsin B
N#Cc1nc(NCc2ccc(Cl)c(Cl)c2)c2ncn(CCCCCO)c2n1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
Cc1cccc(C[C@H](NC(=O)c2ccc(F)cc2F)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'='	6.8	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate measured at 20 mins by fluorescence based assay
N#Cc1nc(Nc2ccc([N+](=O)[O-])cc2)nc(NC2CCCCC2)n1	IC50				Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectromicrofluorimetric method
COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C(=O)CO)cc12	IC50	'='	1300.0	nM	Inhibition of human Cathepsin B using Z-Leu-Arg-AMC as fluorogenic substrate incubated for 60 mins by FRET assay
CCOC(=O)/C=C/C(=O)[C@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)N1CCOCC1	IC50	'='	70.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CCOC(=O)/C=C/[C@H](O)[C@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	52600.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
N#CCNC(=O)C1(NC(=O)c2ccc(-c3ccc(N4CCNCC4)cc3)cc2)CCCCC1	IC50	'='	614.0	nM	Inhibitory activity against cathepsin B from human
CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)c1ccncc1)C(C)(C)C)C(=O)C(=O)NC1CCCCC1	IC50	'='	231.0	nM	Inhibition of human liver cathepsin B using ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH as substrate after 10 mins by fluorescence assay
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCNC(=N)N	IC50	'='	0.0092	ug.mL-1	Inhibitory activity against Cathepsin B was determined
CCCc1cc(-c2cccc(S(C)(=O)=O)c2)nc(C#N)n1	IC50	'>'	10000.0	nM	Inhibition of human recombinant cathepsin B
COc1cc(Cl)cc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C#N)C[C@@H]3CCCNC3=O)cc12	IC50	'='	18000.0	nM	Inhibition of human cathepsin B
CCOC(=O)/C=C/C(=O)[C@@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)N1CCOCC1	IC50	'='	80.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CCOC(=O)/C=C/C(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	60.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CCCC[C@@H](C=O)NC(=O)OC1(Cc2ccccc2)CCCC1	IC50	'='	810.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
CC(C)=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@]2(CC=C(C)C)C(=O)[C@@]1(CC=C(C)C)C(=O)C(C(=O)c1ccc(O)c(O)c1)=C2O	IC50	'='	2100.0	nM	Inhibition of cathepsin B by spectrofluorimetry
CC(=O)N(Cc1ccccc1)C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'>'	100000.0	nM	Inhibition of cathepsin-B using Z-Arg-Arg AMC as substrate by fluorescence assay
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	5239.0	nM	Inhibition of human cathepsin B
Cc1cccc(C[C@H](NC(=O)c2ccc(F)cc2F)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'<'	10.0	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C3CNCCN3)cc2)c1	IC50	'>'	10000.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
N=C(N)c1ccc(/N=N/Nc2ccc(C(=N)N)cc2)cc1	IC50	'>'	30000.0	nM	Inhibition of human liver cathepsin B
CCOC(=O)[C@@H]1O[C@H]1C(=O)N(CC(N)=O)NC(=O)C1CCCN1C(C)=O	IC50	'='	390000.0	nM	Inhibition Assay: Assay buffers consist of 20 mM citric acid, 60 mM disodium hydrogen orthophosphate, 1 mM EDTA, 0.1% CHAPS, 4 mM DTT, pH 5.8 for legumain, 50 mM dihydrogen sodium orthophosphate, 1 mM EDTA, 5 mM DTT, pH 6.25 for cathepsin B and cathepsin Land 100 mM Tris, 0.1% CHAPS, 10% sucrose, 10 mM DTT, pH 7.4 for caspase-3. Concentrations of substrates during the measurement were 10 nM (legumain, cathepsin Land caspase-3) and 50 nM (cathepsin B) and concentration of enzymes were 100 nM for cathepsin Land caspase-3, 270 nM for legumain and 360 nM for cathepsin B. Each enzyme was incubated with inhibitor concentrations ranging from 1 nM to 1 mM in the presence of the substrates.
CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)NCCc1ccc(O)cc1)C(C)CC	IC50	'='	780.0	nM	Inhibition Assay: Assay buffers consist of 20 mM citric acid, 60 mM disodium hydrogen orthophosphate, 1 mM EDTA, 0.1% CHAPS, 4 mM DTT, pH 5.8 for legumain, 50 mM dihydrogen sodium orthophosphate, 1 mM EDTA, 5 mM DTT, pH 6.25 for cathepsin B and cathepsin Land 100 mM Tris, 0.1% CHAPS, 10% sucrose, 10 mM DTT, pH 7.4 for caspase-3. Concentrations of substrates during the measurement were 10 nM (legumain, cathepsin Land caspase-3) and 50 nM (cathepsin B) and concentration of enzymes were 100 nM for cathepsin Land caspase-3, 270 nM for legumain and 360 nM for cathepsin B. Each enzyme was incubated with inhibitor concentrations ranging from 1 nM to 1 mM in the presence of the substrates.
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OCc1ccccc1	IC50	'='	69.7	nM	Compound was tested for its inhibitory activity against cathepsin B
Cc1cccc(C[C@H](NC(=O)c2ccccc2)C(=O)N[C@H](C#N)COCc2cccc(C(=O)O)c2)c1	IC50	'<'	10.0	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
CCOC(=O)/C=C/C(=O)[C@H](CCc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)N1CCOCC1	IC50	'='	140.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
N#Cc1nc(Nc2cccc(F)c2)nc(NC2CCNCC2)n1	IC50	'='	1700.0	nM	Inhibition of human cathepsin B using Z-Phe-Arg-AMC as substrate after 30 mins by spectrofluorimetric method
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	4807.0	nM	Inhibition of cathepsin B in human HepG2 cells
CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1	IC50	'='	61.0	nM	Inhibition of cathepsin B in human HepG2 cells
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3ccc(F)cc3)CC2)CC1	IC50	'='	1000.0	nM	Inhibition of human recombinant cathepsin B using Z-Arg-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay
CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)COC(=O)c1c(C)cccc1C	IC50	'>'	1000000.0	nM	Inhibition Assay: Assay buffers consist of 20 mM citric acid, 60 mM disodium hydrogen orthophosphate, 1 mM EDTA, 0.1% CHAPS, 4 mM DTT, pH 5.8 for legumain, 50 mM dihydrogen sodium orthophosphate, 1 mM EDTA, 5 mM DTT, pH 6.25 for cathepsin B and cathepsin Land 100 mM Tris, 0.1% CHAPS, 10% sucrose, 10 mM DTT, pH 7.4 for caspase-3. Concentrations of substrates during the measurement were 10 nM (legumain, cathepsin Land caspase-3) and 50 nM (cathepsin B) and concentration of enzymes were 100 nM for cathepsin Land caspase-3, 270 nM for legumain and 360 nM for cathepsin B. Each enzyme was incubated with inhibitor concentrations ranging from 1 nM to 1 mM in the presence of the substrates.
[2H]C([2H])(OC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O)C(C)(C)Oc1ccc(Cl)cc1	IC50	'='	800.0	nM	Inhibition of human Cathepsin B
COc1cc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)[C@H](C)C2)ccc1C1CC1	IC50	'='	1140.0	nM	Inhibition of human recombinant cathepsin-B using Z-Arg-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay
Cc1cccc(C[C@H](NC(=O)C(c2ccccc2)c2ccccc2)C(=O)NCC#N)c1	IC50	'='	87.0	nM	Inhibitory activity against recombinant human cathepsin B (cat B) expressed in baculovirus.
Cc1cccc(C)c1-c1cccc(CNc2nc(C#N)nc3c2ncn3CCCO)c1	IC50	'>'	15000.0	nM	Inhibition of human liver cathepsin B
O=C(NCc1cccs1)[C@@H]1CN(C(=O)c2cncc3ccccc23)CCN1c1ccc(Cl)c(Cl)c1	IC50	'='	50000.0	nM	Inhibition of human Cathepsin B using Z-Leu-Arg-AMC as fluorogenic substrate incubated for 60 mins by FRET assay
CCOC(=O)/C=C/C(=O)[C@H](CCc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1	IC50	'='	50.0	nM	Inhibition of human cathepsin B using Cbz-Phe-Arg-AMC as substrate
CC(C)CC(C(=O)NCC#N)c1cccc(-c2ccc(C3CNCCN3)cc2)c1	IC50	'='	1249.0	nM	In vitro inhibitory activity against human cathepsin B, using 2 uM of Z -Leu-Arg-AMC as substrate
O=C(NCc1cccs1)[C@@H]1CN(C(=O)CCl)CCN1c1ccc(Cl)c(Cl)c1	IC50	'>'	30000.0	nM	Inhibition of human cathepsin B using Z-Leu-Arg-AMC as substrate by FRET assay
NC(=S)N/N=C1\CCOc2ccc(Cl)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
Cc1ccc(S(=O)(=O)n2nc(OC(=O)c3cccs3)cc2N)cc1	IC50	'='	1990.0	nM	Inhibition of human liver cathepsin B
CCCC[C@@H](/C=N/NC(=O)N1CCc2ccccc21)NC(=O)OC1(Cc2ccccc2)CCCC1	IC50	'='	1800.0	nM	Inhibition of recombinant human cathepsin B in a fluorescence assay
CC(C)C[C@H](Nc1cscc1-c1ccc(N2CCNCC2)cc1)C(=O)NCC#N	IC50	'='	123.0	nM	Inhibitory concentration against human cathepsin B
NC(=S)N/N=C1\CCc2ccccc2C1	IC50	'>'	10000.0	nM	Inhibition of human liver Cathepsin B using Z-Arg-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis
N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCc3[nH]c4c(OC(F)(F)F)cccc4c3C2)CC1	IC50	'>'	2900.0	nM	Inhibition of human recombinant CatB assessed as suppression of enzyme-mediated Z-Arg-Arg-AMC cleavage by QFRET assay
CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](/C=C/S(=O)(=O)c1ccccc1)CCc1ccccc1	IC50	'='	3.0	nM	Inhibition of human cathepsin-B
C[C@@H](CC1CCCCC1)OC(=O)N[C@H]1CCN(C#N)C1	IC50	'='	680.0	nM	Inhibitory concentration against human cathepsin B using 10 uM Cbz-Phe-Arg-AMC
Nc1cc(OC(=O)c2ccco2)nn1S(=O)(=O)c1ccc(F)cc1	IC50	'='	1260.0	nM	Inhibition of human liver cathepsin B
CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	IC50	'='	14390.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@H](Cc2ccccc2)NC(=O)C2CCN(C(=O)OCc3ccccc3)CC2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
O=C(OC[C@@H](Cc1ccccc1)NS(=O)(=O)c1ccc(Br)cc1)[C@@H](Cc1ccccc1)NS(=O)(=O)c1ccccc1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
COC1=CC(=O)N(C(=O)/C=C/[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2CCCCC2)NC(=O)C2CCN(C)CC2)[C@H]1Cc1c[nH]c2ccccc12	IC50	'='	2.78	10^-4microM	Inhibition of human recombinant Cathepsin B assessed remaining activity using Z-FR-AMC as substrate incubated for 30 mins by fluorometric assay
Nc1cc(OC(=O)c2cccs2)nn1S(=O)(=O)c1ccccc1	IC50	'='	9000.0	nM	Inhibition of human liver cathepsin B pre-incubated for 2 hrs in assay buffer with DTT
CC(C)C[C@@H](C(=O)NCC#N)c1cccc(-c2ccc(N3CCNCC3)cc2)c1	IC50	'='	3950.0	nM	Inhibitory activity against cathepsin B from human
Cn1cnc(Cn2c(=O)[nH]/c(=N\c3cc4cn(C)nc4cc3Cl)n(Cc3cc(F)c(F)cc3F)c2=O)n1	IC50	'>'	100000.0	nM	Inhibition of human liver cathepsin B using Boc-Leu-Arg-Arg-AMC as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by measuring amount of AMC formed by spectrofluorimetric method
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C(=O)O	IC50	'='	17.7	nM	Compound was tested for its inhibitory activity against cathepsin B
CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@H]1CC[C@@H](C)N(S(=O)(=O)c2ccccn2)CC1=O	IC50	'='	14.0	nM	Inhibition of cathepsin B in human HepG2 cells
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(N3CCNCC3)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	82.0	nM	Potency against Cathepsin B in HepG2 cells by whole cell enzyme occupancy assay
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(N3CCNCC3)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	1111.0	nM	Inhibitory activity against cathepsin B from human
N#CCNC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	62000.0	nM	Inhibition of recombinant human cathepsin B expressed in baculovirus expression system using Z-Arg-Arg-AMC as substrate incubated for 20 mins by fluorescence based assay
	IC50	'='	250000.0	nM	Inhibitory concentration against human liver cathepsin B
O=C[C@@H](Cc1c[nH]c2ccccc12)NC(=O)CNS(=O)(=O)c1cccc2ccccc12	IC50	'>'	1000.0	nM	Inhibition of human cathepsin B
CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)[C@@H](C)CC	IC50	'='	2.44	nM	Inhibition of cathepsin B in human SH-SY5Y cells using RR-AMC as substrate by fluorescence microplate reader assay
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
N#Cc1ccccc1N1CCN(C[C@H](O)COC[C@H](Cc2ccccc2)NS(=O)(=O)c2ccc(Br)cc2)CC1	IC50	'>'	100000.0	nM	Inhibition of human cathepsin B
O=C(CF)CNC(=O)[C@H](Cc1ccccc1)NC(=O)c1cccc2ccccc12	IC50	'='	200.0	nM	Inhibition of recombinant human cathepsin B (332 residues) expressed in CHO cells using Z-FR-AMC as substrate preincubated for 20 mins followed by substrate addition by fluorescence plate reader analysis
CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)NC(C=O)Cc1ccccc1	IC50	'='	95.8	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
NC(=S)N/N=C(\c1cccc(O)c1)c1cccc(Br)c1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
CC(C)C[C@H](NC(=O)c1cc2c(F)cccc2[nH]1)C(=O)NN(C[C@@H]1CCNC1=O)C(=O)[C@H](F)Cl	IC50	'>'	50000.0	nM	Inhibition of C-terminal His-tagged Human cathepsin B expressed in FreeStyle 293-F cells using Z-Leu-Arg-MCA peptide as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by multimode plate reader analysis
NC(=S)NN=C(c1ccccc1)c1ccccc1	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B after 5 mins by microplate reader analysis
COC1=CC(=O)N(C(=O)/C=C/[C@H](C)NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](C(C)C)N(C)C)[C@H]1Cc1c[nH]c2ccccc12	IC50	'='	4.76	10^-2microM	Inhibition of human recombinant Cathepsin B assessed remaining activity using Z-FR-AMC as substrate incubated for 30 mins by fluorometric assay
CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1	IC50	'>'	100000.0	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate preincubated for 30 mins followed by substrate addition and further incubated for 30 mins under shaking condition by fluorescence assay
CN1CCN(C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](/C=C/S(=O)(=O)c2ccccc2)CCc2ccccc2)CC1	IC50	'='	5.7	nM	Inhibition of human Cathepsin B using Cbz-Phe-Arg-AMC as substrate by fluorescence assay
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)CF)OCc1ccccc1	IC50	'='	65.6	nM	Inhibition of cathepsin B (unknown origin) using RR-AMC as substrate after 30 mins by fluorescence assay
CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)OC)[C@@H](C)CC	IC50	'='	80.0	nM	Inhibition of cathepsin-B using Z-Arg-Arg AMC as substrate by fluorescence assay
CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)[O-].[Na+]	IC50	'='	1400.0	nM	Inhibition of human cathepsin B
NC(=S)N/N=C1\CCSc2ccc(Cl)cc21	IC50	'>'	10000.0	nM	Inhibition of human liver cathepsin B using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis
CC(C)(C)[C@H](NC(=O)C(F)(F)F)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@H](C#N)C[C@@H]1CCNC1=O)C2(C)C	IC50	'>'	30000.0	nM	Inhibition of human Cathepsin B
CC[C@H](C)[C@@H](C(=O)O[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)/C=C/C(=O)N1C(=O)C=C(OC)[C@@H]1C)N(C)C	IC50	'='	7.34	nM	Inhibition of human recombinant Cathepsin B assessed remaining activity using Z-FR-AMC as substrate incubated for 30 mins by fluorometric assay
CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)O)C(C)C)C(C)C	IC50	'='	10000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-AMC as substrate after 30 mins by fluorescence assay
CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N	IC50	'='	1500.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(C)=O)C(=O)N[C@H](C=O)CCCN=C(N)N	IC50	'='	150.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C=O)CCCN=C(N)N)C(C)C	IC50	'='	130000.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N)C(C)C	IC50	'='	100000.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCCN	IC50	'='	18000.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC[C@H](C)[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCCN	IC50	'='	2000.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
COc1ccccc1/C=C/C(=O)N[C@@H](COC(=O)c1ccccc1)C(=O)NC1CCCCC1	IC50	'='	170000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-MCA as substrate incubated for 10 mins
COc1cc(/C=C/C(=O)N[C@H](COC(=O)c2ccccc2)C(=O)NC2CCCCC2)cc(OC)c1OC	IC50	'='	500000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-MCA as substrate incubated for 10 mins
CC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCCN)C(C)C	IC50	'='	28000.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C=O)CCCCN)C(C)C	IC50	'='	4.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@H](C=O)CCCN=C(N)N)C(C)C	IC50	'='	39.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCCN	IC50	'='	130.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
C[C@H]([C@@H]1C[C@H]2C[C@](C)(OC2(C)C)[C@@H](CC[C@@H](C)[C@H]2CC[C@H]3C4=C(CC[C@]23C)[C@@]2(C)C[C@H](OS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@H](C)C2=CC4)O1)[C@H]1CC[C@H]2C3=C(CC[C@]12C)[C@]12CC[C@](O)(OC1)[C@@H](C)[C@@H]2[C@@H](OS(=O)(=O)[O-])C3.[Na+].[Na+].[Na+]	IC50	'='	8.0	ug.mL-1	Inhibition of bovine cathepsin B after 1 hr by fluorescence assay
C[C@H]([C@@H]1C[C@H]2C[C@](C)(OC2(C)C)[C@@H](CC[C@@H](C)[C@H]2CC=C3C4=C(CC[C@@]32C)[C@@]2(C)C[C@H](OS(=O)(=O)[O-])[C@@H](OS(=O)(=O)[O-])[C@H](C)C2=CC4)O1)[C@H]1CC[C@H]2C3=C(CC[C@]12C)[C@]12CC[C@](O)(OC1)[C@@H](C)[C@@H]2[C@@H](OS(=O)(=O)[O-])C3.[Na+].[Na+].[Na+]	IC50	'='	8.0	ug.mL-1	Inhibition of bovine cathepsin B after 1 hr by fluorescence assay
CC[C@H](C)[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N	IC50			nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester; Not significantly active
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C=O)CCCCN	IC50	'='	100.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CC(=O)O)C(C)C)C(C)C	IC50	'='	25000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-AMC as substrate after 30 mins by fluorescence assay
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C=O)CCCN=C(N)N	IC50	'='	1600.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(C)C)C(C)C)C(C)C)[C@@H](O)CC(=O)O	IC50	'='	29000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-AMC as substrate after 30 mins by fluorescence assay
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCNC(=N)N	IC50	'='	310.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CSCC[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC1=O	IC50	'>'	500000.0	nM	Inhibition of bovine Cathepsin B
CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C=O)CCCN=C(N)N	IC50	'='	1100.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(C)C)C(C)C)C(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CC(=O)O	IC50	'='	26000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-AMC as substrate after 30 mins by fluorescence assay
CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N	IC50	'='	22000.0	nM	Inhibition of cathepsin B with Cbz-L-lysine-p-nitrophenyl ester as substrate
CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)O)C(C)C)C(C)C	IC50	'='	17000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-AMC as substrate after 30 mins by fluorescence assay
CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)CC(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CC(=O)O)C(C)C)C(C)C	IC50	'='	15000.0	nM	Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-AMC as substrate after 30 mins by fluorescence assay
N#CC1(NC(=O)[C@H](CS(=O)(=O)Cc2cccc(F)c2F)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	384.0	nM	Inhibition of rat liver lysosomal cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N[C@H]1S(=O)(=O)c1ccccc1)OCc1ccccc1	IC50	'='	7390.0	nM	Inhibition of recombinant rat Cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N[C@@H]1Sc1ccccc1)OCc1ccccc1	IC50	'='	39700.0	nM	Inhibition of recombinant rat Cathepsin B
O=C(CCc1ccccc1)O[C@@H]1NC(=O)[C@H]1NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	9710.0	nM	Inhibition of recombinant rat Cathepsin B
C[S+]([O-])C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'>'	10000.0	nM	Inhibition of rat liver lysosomal cathepsin B
CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)COC(=O)c1c(C)cccc1C	IC50	'='	7.3	nM	Binding affinity to cathepsin B in crude rat liver homogenates using [125I]DCG-04 based competition protein labeling by SDS-PAGE method
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1CNC1=O)OCc1ccccc1	IC50	'='	13600.0	nM	Inhibition of recombinant rat Cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CNC1=O)OCc1ccccc1	IC50	'='	2700.0	nM	Inhibition of recombinant rat Cathepsin B
CC(=O)O[C@@H]1NC(=O)[C@H]1NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	470.0	nM	Inhibition of recombinant rat Cathepsin B
Cc1cccc(C)c1C(=O)OCC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1	IC50	'='	920.0	nM	Binding affinity to cathepsin B in crude rat liver homogenates using [125I]DCG-04 based competition protein labeling by SDS-PAGE method
CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](/C=C/S(=O)(=O)c1ccccc1)CCc1ccccc1	IC50	'='	735.0	nM	Inhibition of rat liver lysosomal cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(Cl)c(Cl)c2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	5694.0	nM	Inhibition of rat liver lysosomal cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(Br)cc2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	1809.0	nM	Inhibition of rat liver lysosomal cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2cccc(Br)c2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	4702.0	nM	Inhibition of rat liver lysosomal cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N[C@@H]1Oc1ccccc1)OCc1ccccc1	IC50	'='	430.0	nM	Inhibition of recombinant rat Cathepsin B
CC(C)(C)O[C@@H]1NC(=O)[C@H]1NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	11400.0	nM	Inhibition of recombinant rat Cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N[C@H]1Sc1ccccc1)OCc1ccccc1	IC50	'='	10500.0	nM	Inhibition of recombinant rat Cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N[C@H]1Oc1ccccc1)OCc1ccccc1	IC50	'='	10900.0	nM	Inhibition of recombinant rat Cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	319.0	nM	Inhibition of rat liver lysosomal cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)CC2CC2)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	272.0	nM	Inhibition of rat liver lysosomal cathepsin B
COc1ccc(C(=O)ONC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2ccccc2)cc1	IC50	'='	1200.0	nM	Binding affinity to cathepsin B in crude rat liver homogenates using [125I]DCG-04 based competition protein labeling by SDS-PAGE method
Cc1cccc(C)c1C(=O)OCC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	120.0	nM	Binding affinity to cathepsin B in crude rat liver homogenates using [125I]DCG-04 based competition protein labeling by SDS-PAGE method
CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)COC(=O)c1c(C)cccc1C	IC50	'='	220.0	nM	Binding affinity to cathepsin B in crude rat liver homogenates using [125I]DCG-04 based competition protein labeling by SDS-PAGE method
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N[C@H]1OC(=O)c1ccccc1)OCc1ccccc1	IC50	'='	27500.0	nM	Inhibition of recombinant rat Cathepsin B
CCCCO[C@@H]1NC(=O)[C@H]1NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	7010.0	nM	Inhibition of recombinant rat Cathepsin B
O=C(N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1C(=O)N[C@H]1OCc1ccccc1)OCc1ccccc1	IC50	'='	32570.0	nM	Inhibition of recombinant rat Cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	925.0	nM	Inhibition of rat liver lysosomal cathepsin B
CC(C)CO[C@@H]1NC(=O)[C@H]1NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	6460.0	nM	Inhibition of recombinant rat Cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	66.0	nM	Inhibition of rat liver lysosomal cathepsin B
Cc1cccc(C)c1C(=O)OCC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1	IC50	'='	15.0	nM	Binding affinity to cathepsin B in crude rat liver homogenates using [125I]DCG-04 based competition protein labeling by SDS-PAGE method
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(Cl)c(Cl)c2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	3018.0	nM	Inhibition of mouse recombinant cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2ccc(Br)cc2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	1747.0	nM	Inhibition of mouse recombinant cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)Cc2cccc(F)c2F)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	384.0	nM	Inhibition of mouse recombinant cathepsin B
CC(C)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NCC#N	IC50	'='	540.0	nM	Inhibition of mouse recombinant cathepsin B
CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](/C=C/S(=O)(=O)c1ccccc1)CCc1ccccc1	IC50	'='	1277.0	nM	Inhibition of mouse recombinant cathepsin B
C[S+]([O-])C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	6702.0	nM	Inhibition of mouse recombinant cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)CC2CC2)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1	IC50	'='	253.0	nM	Inhibition of mouse recombinant cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	233.0	nM	Inhibition of mouse recombinant cathepsin B
CS(=O)(=O)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1	IC50	'='	69.0	nM	Inhibition of mouse recombinant cathepsin B
N#CC1(NC(=O)[C@H](CS(=O)(=O)c2cccc(Br)c2)N[C@@H](c2ccccc2)C(F)(F)F)CC1	IC50	'='	4013.0	nM	Inhibition of mouse recombinant cathepsin B
CCCCOC(=O)c1ccccc1C(=O)OCCCC	IC50	'='	230000.0	nM	Inhibition of cathepsin B in mouse B16F10 cells
CCCC[C@@H](CC)COC(=O)c1ccccc1C(=O)OC[C@@H](CC)CCCC	IC50	'='	140000.0	nM	Inhibition of cathepsin B in mouse B16F10 cells
O=[N+]([O-])c1ccc(C2CC(c3ccccc3)=NN2)cc1	IC50	'='	740.0	nM	Inhibition of goat liver cathepsin B using BANA substrate pre-incubated 30 mins before substrate addition by colorimetry
O=[N+]([O-])c1ccc(-c2cc(-c3ccccc3)nn2-c2ccccc2)cc1	IC50	'='	5680.0	nM	Inhibition of goat liver cathepsin B using BANA substrate pre-incubated 30 mins before substrate addition by colorimetry
CC(=O)N1N=C(c2ccccc2)CC1c1ccc([N+](=O)[O-])cc1	IC50	'='	5900.0	nM	Inhibition of goat liver cathepsin B using BANA substrate pre-incubated 30 mins before substrate addition by colorimetry
O=[N+]([O-])c1ccc(/C=C/C(=N\Nc2ccccc2)c2ccccc2)cc1	IC50	'='	450.0	nM	Inhibition of goat liver cathepsin B using BANA substrate pre-incubated 30 mins before substrate addition by colorimetry
O=[N+]([O-])c1ccc(C2CC(c3ccccc3)=NN2c2ccccc2)cc1	IC50	'='	500.0	nM	Inhibition of goat liver cathepsin B using BANA substrate pre-incubated 30 mins before substrate addition by colorimetry
